{
  "metadata": {
    "graph_path": "./logic_graph.png",
    "num_solutions": 13,
    "family_stats": {
      "1": {
        "core": 1,
        "branch": 3
      },
      "2": {
        "core": 1,
        "branch": 0
      },
      "3": {
        "core": 1,
        "branch": 3
      },
      "4": {
        "core": 1,
        "branch": 3
      }
    }
  },
  "knowledge_base": {
    "rules": [
      {
        "id": "Rule1",
        "formal": "(A10 → (¬G → A8))",
        "prover9_expression": "(breakthrough_therapy(drug) -> (-profitable(drug) -> clinical_trial_completed(drug)))",
        "natural": "Provided that the drug is designated as a breakthrough therapy, if the drug is not profitable, then the clinical trial for the drug is completed."
      },
      {
        "id": "Rule2",
        "formal": "(A11 ∨ (A9 ∨ A10))",
        "prover9_expression": "(manufacturing_issue(drug) | (fast_track_approval(drug) | breakthrough_therapy(drug)))",
        "natural": "Either there is a manufacturing issue with the drug, or the drug receives fast track approval, or the drug is designated as a breakthrough therapy."
      },
      {
        "id": "Rule3",
        "formal": "(A12 → ¬A11)",
        "prover9_expression": "(contamination_found(drug) -> -manufacturing_issue(drug))",
        "natural": "Whenever contamination is found in the drug, it is not the case that there is a manufacturing issue with the drug."
      },
      {
        "id": "Rule4",
        "formal": "(A12 ∨ A13)",
        "prover9_expression": "(contamination_found(drug) | quality_control_failure(drug))",
        "natural": "Either contamination is found in the drug or there is a quality control failure for the drug."
      },
      {
        "id": "Rule5",
        "formal": "(A13 → A14)",
        "prover9_expression": "(quality_control_failure(drug) -> recall_issued(drug))",
        "natural": "Under the condition that there is a quality control failure for the drug, a recall is issued for the drug."
      },
      {
        "id": "Rule6",
        "formal": "(A15 ∨ (A14 → ¬A11))",
        "prover9_expression": "(market_withdrawal(drug) | (recall_issued(drug) -> -manufacturing_issue(drug)))",
        "natural": "Either the drug undergoes market withdrawal, or if a recall is issued for the drug, then it is not the case that there is a manufacturing issue with the drug."
      },
      {
        "id": "Rule7",
        "formal": "(A16 → G)",
        "prover9_expression": "(financial_investment(company,drug) -> profitable(drug))",
        "natural": "Provided that the company makes a financial investment in the drug, the drug is profitable."
      },
      {
        "id": "Rule8",
        "formal": "(A17 → G)",
        "prover9_expression": "(venture_capital_funding(drug) -> profitable(drug))",
        "natural": "If the drug receives venture capital funding, then the drug is profitable."
      },
      {
        "id": "Rule9",
        "formal": "(A18 → A16)",
        "prover9_expression": "(initial_public_offering(company) -> financial_investment(company,drug))",
        "natural": "Provided that the company conducts an initial public offering, the company makes a financial investment in the drug."
      },
      {
        "id": "Rule10",
        "formal": "(A18 ∨ A19)",
        "prover9_expression": "(initial_public_offering(company) | private_equity_investment(drug))",
        "natural": "Either the company conducts an initial public offering or the drug receives private equity investment."
      },
      {
        "id": "Rule11",
        "formal": "(A2 → A3)",
        "prover9_expression": "(submitted(application,regulatory_agency) -> reviewed(application,regulatory_agency))",
        "natural": "Provided that an application is submitted to the regulatory agency, the application is reviewed by the regulatory agency."
      },
      {
        "id": "Rule12",
        "formal": "(A20 → (A19 → A17))",
        "prover9_expression": "(successful_phase3_trial(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))",
        "natural": "Given that the drug has a successful phase 3 trial, if the drug receives private equity investment, then the drug receives venture capital funding."
      },
      {
        "id": "Rule13",
        "formal": "(A20 ∨ A21)",
        "prover9_expression": "(successful_phase3_trial(drug) | regulatory_approval(drug))",
        "natural": "Either the drug has a successful phase 3 trial or the drug receives regulatory approval."
      },
      {
        "id": "Rule14",
        "formal": "(A21 → A23)",
        "prover9_expression": "(regulatory_approval(drug) -> marketing_campaign(drug))",
        "natural": "If the drug receives regulatory approval, then a marketing campaign is conducted for the drug."
      },
      {
        "id": "Rule15",
        "formal": "(A21 → A60)",
        "prover9_expression": "(regulatory_approval(drug) -> reimbursement_approval(drug))",
        "natural": "Under the condition that the drug receives regulatory approval, the drug receives reimbursement approval."
      },
      {
        "id": "Rule16",
        "formal": "(A22 → (A19 → A17))",
        "prover9_expression": "(market_launch(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))",
        "natural": "Provided that the drug is launched on the market, if the drug receives private equity investment, then the drug receives venture capital funding."
      },
      {
        "id": "Rule17",
        "formal": "(A23 → A22)",
        "prover9_expression": "(marketing_campaign(drug) -> market_launch(drug))",
        "natural": "If a marketing campaign is conducted for the drug, then the drug is launched on the market."
      },
      {
        "id": "Rule18",
        "formal": "(A24 ∨ A25)",
        "prover9_expression": "(blockchain_tracking(drug) | traditional_tracking(drug))",
        "natural": "Either the drug uses blockchain tracking or the drug uses traditional tracking."
      },
      {
        "id": "Rule19",
        "formal": "(A25 → G)",
        "prover9_expression": "(traditional_tracking(drug) -> profitable(drug))",
        "natural": "Provided that the drug uses traditional tracking, the drug is profitable."
      },
      {
        "id": "Rule20",
        "formal": "(A26 → A63)",
        "prover9_expression": "(counterfeit_product(drug) -> generic_competition(drug))",
        "natural": "Whenever the drug is a counterfeit product, the drug faces generic competition."
      },
      {
        "id": "Rule21",
        "formal": "(A26 → ¬A27)",
        "prover9_expression": "(counterfeit_product(drug) -> -authentic_product(drug))",
        "natural": "Provided that the drug is a counterfeit product, it is not the case that the drug is an authentic product."
      },
      {
        "id": "Rule22",
        "formal": "(A26 ∨ (A24 → G))",
        "prover9_expression": "(counterfeit_product(drug) | (blockchain_tracking(drug) -> profitable(drug)))",
        "natural": "Either the drug is a counterfeit product, or if the drug uses blockchain tracking, the drug is profitable."
      },
      {
        "id": "Rule23",
        "formal": "(A28 → A72)",
        "prover9_expression": "(illegal_distribution(drug) -> supply_chain_disruption(drug))",
        "natural": "If the drug is distributed illegally, then the drug experiences a supply chain disruption."
      },
      {
        "id": "Rule24",
        "formal": "(A28 → A76)",
        "prover9_expression": "(illegal_distribution(drug) -> storage_violation(drug))",
        "natural": "Under the condition that the drug is distributed illegally, there is a storage violation for the drug."
      },
      {
        "id": "Rule25",
        "formal": "(A29 ∨ ¬A28)",
        "prover9_expression": "(legal_distribution(drug) | -illegal_distribution(drug))",
        "natural": "Either the drug is distributed legally or the drug is not distributed illegally."
      },
      {
        "id": "Rule26",
        "formal": "(A32 → (A31 ∨ ¬A30))",
        "prover9_expression": "(compliance_certificate(drug) -> (full_approval(drug) | -conditional_approval(drug)))",
        "natural": "If the drug has a compliance certificate, then either the drug receives full approval or the drug does not receive conditional approval."
      },
      {
        "id": "Rule27",
        "formal": "(A33 ∨ A34)",
        "prover9_expression": "(internal_audit(company) | external_audit(company))",
        "natural": "Either the company undergoes an internal audit or the company undergoes an external audit."
      },
      {
        "id": "Rule28",
        "formal": "(A34 → A32)",
        "prover9_expression": "(external_audit(company) -> compliance_certificate(drug))",
        "natural": "Provided that the company undergoes an external audit, the drug has a compliance certificate."
      },
      {
        "id": "Rule29",
        "formal": "(A36 ∨ ¬A35)",
        "prover9_expression": "(compliance_maintained(company) | -regulatory_violation(company))",
        "natural": "Either the company maintains compliance or the company does not commit a regulatory violation."
      },
      {
        "id": "Rule30",
        "formal": "(A37 ∨ A38)",
        "prover9_expression": "(accelerated_review(drug) | standard_review(drug))",
        "natural": "Either the drug undergoes an accelerated review or the drug undergoes a standard review."
      },
      {
        "id": "Rule31",
        "formal": "(A38 → (A5 → (A3 → (¬G → ¬A1))))",
        "prover9_expression": "(standard_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))",
        "natural": "Given that the drug undergoes a standard review, if the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, it is not the case that the technology for the drug is approved."
      },
      {
        "id": "Rule32",
        "formal": "(A4 → (A3 → (¬G → ¬A1)))",
        "prover9_expression": "(requires_clinical_trials(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug))))",
        "natural": "Provided that clinical trials are required for the drug, if the application is reviewed by the regulatory agency, then given that the drug is not profitable, the technology for the drug is not approved."
      },
      {
        "id": "Rule33",
        "formal": "(A4 ∨ A5)",
        "prover9_expression": "(requires_clinical_trials(drug) | meets_safety_standards(drug))",
        "natural": "Either clinical trials are required for the drug or the drug meets safety standards."
      },
      {
        "id": "Rule34",
        "formal": "(A40 → (A39 ∨ (A37 → (A5 → (A3 → (¬G → ¬A1))))))",
        "prover9_expression": "(rare_disease_indication(drug) -> (orphan_drug_status(drug) | (accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))))",
        "natural": "If the drug has a rare disease indication, then either the drug has orphan drug status, or provided that the drug undergoes an accelerated review, then if the drug meets safety standards, whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
      },
      {
        "id": "Rule35",
        "formal": "(A40 ∨ A41)",
        "prover9_expression": "(rare_disease_indication(drug) | common_disease_indication(drug))",
        "natural": "Either the drug has a rare disease indication or the drug has a common disease indication."
      },
      {
        "id": "Rule36",
        "formal": "(A42 ∨ (A41 → (A39 ∨ (A37 → (A5 → (A3 → (¬G → ¬A1)))))))",
        "prover9_expression": "(combination_therapy(drug) | (common_disease_indication(drug) -> (orphan_drug_status(drug) | (accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug))))))))",
        "natural": "Either the drug is a combination therapy, or if the drug has a common disease indication, then either the drug has orphan drug status, or provided that the drug undergoes an accelerated review, then if the drug meets safety standards, given that the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
      },
      {
        "id": "Rule37",
        "formal": "(A43 → A44)",
        "prover9_expression": "(drug_interaction_issue(drug) -> adverse_events(drug))",
        "natural": "If the drug has a drug interaction issue, then the drug has adverse events."
      },
      {
        "id": "Rule38",
        "formal": "(A45 → A47)",
        "prover9_expression": "(post_market_surveillance(drug) -> safety_monitoring(drug))",
        "natural": "Whenever the drug undergoes post-market surveillance, the drug undergoes safety monitoring."
      },
      {
        "id": "Rule39",
        "formal": "(A45 ∨ A46)",
        "prover9_expression": "(post_market_surveillance(drug) | pre_market_testing(drug))",
        "natural": "Either the drug undergoes post-market surveillance or the drug undergoes pre-market testing."
      },
      {
        "id": "Rule40",
        "formal": "(A46 → (A43 → ¬A44))",
        "prover9_expression": "(pre_market_testing(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug)))",
        "natural": "Given that the drug undergoes pre-market testing, if the drug has a drug interaction issue, then the drug does not have adverse events."
      },
      {
        "id": "Rule41",
        "formal": "(A53 → (A52 ∨ (¬(A50 ∨ (A19 → A17)) → A51)))",
        "prover9_expression": "(health_economics_study(drug) -> (value_based_pricing(drug) | (-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> price_control(drug))))",
        "natural": "Provided that a health economics study is conducted for the drug, either the drug uses value-based pricing, or if it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, then the drug is under price control."
      },
      {
        "id": "Rule42",
        "formal": "(A53 ∨ A54)",
        "prover9_expression": "(health_economics_study(drug) | outcomes_research(drug))",
        "natural": "Either a health economics study is conducted for the drug or outcomes research is conducted for the drug."
      },
      {
        "id": "Rule43",
        "formal": "(A54 → (A52 ∨ (¬(A50 ∨ (A19 → A17)) → A51)))",
        "prover9_expression": "(outcomes_research(drug) -> (value_based_pricing(drug) | (-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> price_control(drug))))",
        "natural": "If outcomes research is conducted for the drug, then either the drug uses value-based pricing, or given that it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, the drug is under price control."
      },
      {
        "id": "Rule44",
        "formal": "(A57 → A58)",
        "prover9_expression": "(patent_granted(drug) -> patent_exclusivity(drug))",
        "natural": "Under the condition that a patent is granted for the drug, the drug has patent exclusivity."
      },
      {
        "id": "Rule45",
        "formal": "(A58 → A59)",
        "prover9_expression": "(patent_exclusivity(drug) -> patent_extension(drug))",
        "natural": "If the drug has patent exclusivity, then the drug receives a patent extension."
      },
      {
        "id": "Rule46",
        "formal": "(A59 → (A56 → (¬(A21 → A22) → A55)))",
        "prover9_expression": "(patent_extension(drug) -> (patent_filing(drug) -> (-(regulatory_approval(drug) -> market_launch(drug)) -> market_exclusivity(drug))))",
        "natural": "Whenever the drug receives a patent extension, if a patent is filed for the drug, then provided that it is not the case that if the drug receives regulatory approval then the drug is launched on the market, the drug has market exclusivity."
      },
      {
        "id": "Rule47",
        "formal": "(A6 → (A5 → (A3 → (¬G → ¬A1))))",
        "prover9_expression": "(has_patent_protection(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))",
        "natural": "Given that the drug has patent protection, if the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
      },
      {
        "id": "Rule48",
        "formal": "(A63 → ¬A64)",
        "prover9_expression": "(generic_competition(drug) -> -biosimilar_version(drug))",
        "natural": "Under the condition that the drug faces generic competition, it is not the case that a biosimilar version of the drug is available."
      },
      {
        "id": "Rule49",
        "formal": "(A65 → (A63 → A64))",
        "prover9_expression": "(patent_litigation(drug) -> (generic_competition(drug) -> biosimilar_version(drug)))",
        "natural": "If there is patent litigation for the drug, then whenever the drug faces generic competition, a biosimilar version of the drug is available."
      },
      {
        "id": "Rule50",
        "formal": "(A65 ∨ A66)",
        "prover9_expression": "(patent_litigation(drug) | patent_settlement(drug))",
        "natural": "Either there is patent litigation for the drug or there is a patent settlement for the drug."
      },
      {
        "id": "Rule51",
        "formal": "(A68 → A69)",
        "prover9_expression": "(manufacturing_process(technology,drug) -> automated_production(drug))",
        "natural": "Whenever a manufacturing process uses technology for the drug, the drug is produced through automated production."
      },
      {
        "id": "Rule52",
        "formal": "(A68 → A70)",
        "prover9_expression": "(manufacturing_process(technology,drug) -> manual_production(drug))",
        "natural": "If a manufacturing process uses technology for the drug, then the drug is produced through manual production."
      },
      {
        "id": "Rule53",
        "formal": "(A68 ∨ ¬A67)",
        "prover9_expression": "(manufacturing_process(technology,drug) | -patent_infringement(drug))",
        "natural": "Either a manufacturing process uses technology for the drug or there is no patent infringement for the drug."
      },
      {
        "id": "Rule54",
        "formal": "(A70 → A71)",
        "prover9_expression": "(manual_production(drug) -> hybrid_production(drug))",
        "natural": "Under the condition that the drug is produced through manual production, the drug is produced through hybrid production."
      },
      {
        "id": "Rule55",
        "formal": "(A71 → ¬A69)",
        "prover9_expression": "(hybrid_production(drug) -> -automated_production(drug))",
        "natural": "Provided that the drug is produced through hybrid production, the drug is not produced through automated production."
      },
      {
        "id": "Rule56",
        "formal": "(A72 → A73)",
        "prover9_expression": "(supply_chain_disruption(drug) -> production_delayed(drug))",
        "natural": "Given that the drug experiences a supply chain disruption, production of the drug is delayed."
      },
      {
        "id": "Rule57",
        "formal": "(A74 → ¬A73)",
        "prover9_expression": "(alternative_supplier(drug) -> -production_delayed(drug))",
        "natural": "If the drug has an alternative supplier, then production of the drug is not delayed."
      },
      {
        "id": "Rule58",
        "formal": "(A74 ∨ A75)",
        "prover9_expression": "(alternative_supplier(drug) | backup_manufacturer(drug))",
        "natural": "Either the drug has an alternative supplier or the drug has a backup manufacturer."
      },
      {
        "id": "Rule59",
        "formal": "(A75 → ¬A73)",
        "prover9_expression": "(backup_manufacturer(drug) -> -production_delayed(drug))",
        "natural": "Whenever the drug has a backup manufacturer, production of the drug is not delayed."
      },
      {
        "id": "Rule60",
        "formal": "(A76 → A78)",
        "prover9_expression": "(storage_violation(drug) -> humidity_issue(drug))",
        "natural": "If there is a storage violation for the drug, then the drug has a humidity issue."
      },
      {
        "id": "Rule61",
        "formal": "(A79 ∨ (A78 → A77))",
        "prover9_expression": "(quality_assurance(drug) | (humidity_issue(drug) -> temperature_excursion(drug)))",
        "natural": "Either the drug undergoes quality assurance or if the drug has a humidity issue, then the drug experiences a temperature excursion."
      },
      {
        "id": "Rule62",
        "formal": "(A81 ∨ (A80 ∨ ¬A79))",
        "prover9_expression": "(stability_study(drug) | (batch_testing(drug) | -quality_assurance(drug)))",
        "natural": "Either the drug undergoes a stability study, or the drug undergoes batch testing, or the drug does not undergo quality assurance."
      },
      {
        "id": "Rule63",
        "formal": "(A9 → (¬G → A8))",
        "prover9_expression": "(fast_track_approval(drug) -> (-profitable(drug) -> clinical_trial_completed(drug)))",
        "natural": "Provided that the drug receives fast track approval, if the drug is not profitable, then the clinical trial for the drug is completed."
      },
      {
        "id": "Rule64",
        "formal": "(¬(A26 → A27) → A28)",
        "prover9_expression": "(-(counterfeit_product(drug) -> authentic_product(drug)) -> illegal_distribution(drug))",
        "natural": "Provided that it is not the case that if the drug is a counterfeit product then the drug is an authentic product, the drug is distributed illegally."
      },
      {
        "id": "Rule65",
        "formal": "(¬(A33 → A32) → A35)",
        "prover9_expression": "(-(internal_audit(company) -> compliance_certificate(drug)) -> regulatory_violation(company))",
        "natural": "If it is not the case that if the company undergoes an internal audit then the drug has a compliance certificate, then the company commits a regulatory violation."
      },
      {
        "id": "Rule66",
        "formal": "(¬(A5 → (A3 → (¬G → ¬A1))) → A43)",
        "prover9_expression": "(-(meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))) -> drug_interaction_issue(drug))",
        "natural": "Provided that it is not the case that if the drug meets safety standards then if the application is reviewed by the regulatory agency then if the drug is not profitable then the technology for the drug is not approved, the drug has a drug interaction issue."
      },
      {
        "id": "Rule67",
        "formal": "(¬(A50 ∨ (A19 → A17)) → ¬A51)",
        "prover9_expression": "(-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> -price_control(drug))",
        "natural": "Whenever it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, the drug is not under price control."
      },
      {
        "id": "Rule68",
        "formal": "(¬(A61 ∨ (A60 → (A19 → A17))) → A62)",
        "prover9_expression": "(-(formulary_inclusion(drug) | (reimbursement_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))) -> prior_authorization(drug))",
        "natural": "Provided that it is not the case that either the drug is included in a formulary or if the drug receives reimbursement approval then if the drug receives private equity investment then the drug receives venture capital funding, the drug requires prior authorization."
      },
      {
        "id": "Rule69",
        "formal": "(¬(A61 ∨ (A60 → (A19 → A17))) → ¬A62)",
        "prover9_expression": "(-(formulary_inclusion(drug) | (reimbursement_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))) -> -prior_authorization(drug))",
        "natural": "If it is not the case that either the drug is included in a formulary or if the drug receives reimbursement approval then if the drug receives private equity investment then the drug receives venture capital funding, then the drug does not require prior authorization."
      },
      {
        "id": "Rule70",
        "formal": "(¬(A66 → (A63 → A64)) → A67)",
        "prover9_expression": "(-(patent_settlement(drug) -> (generic_competition(drug) -> biosimilar_version(drug))) -> patent_infringement(drug))",
        "natural": "Given that it is not the case that if there is a patent settlement for the drug then if the drug faces generic competition then a biosimilar version of the drug is available, there is patent infringement for the drug."
      },
      {
        "id": "Rule71",
        "formal": "(¬(¬(A47 → (A43 → ¬A44)) → A48) → A49)",
        "prover9_expression": "(-(-(safety_monitoring(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug))) -> risk_management_plan(drug)) -> black_box_warning(drug))",
        "natural": "Provided that it is not the case that if it is not the case that if the drug undergoes safety monitoring then if the drug has a drug interaction issue then the drug does not have adverse events then the drug has a risk management plan, the drug has a black box warning."
      },
      {
        "id": "Rule72",
        "formal": "(¬(¬G → ¬A1) → A30)",
        "prover9_expression": "(-(-profitable(drug) -> -approved(technology,drug)) -> conditional_approval(drug))",
        "natural": "If it is not the case that if the drug is not profitable then the technology for the drug is not approved, then the drug receives conditional approval."
      },
      {
        "id": "Rule73",
        "formal": "(¬A6 → A7)",
        "prover9_expression": "(-has_patent_protection(drug) -> generic_version_available(drug))",
        "natural": "Whenever the drug does not have patent protection, a generic version of the drug is available."
      },
      {
        "id": "Rule74",
        "formal": "(¬A6 → ¬A7)",
        "prover9_expression": "(-has_patent_protection(drug) -> -generic_version_available(drug))",
        "natural": "Provided that the drug does not have patent protection, it is not the case that a generic version of the drug is available."
      },
      {
        "id": "Rule75",
        "formal": "(¬G → A1)",
        "prover9_expression": "(-profitable(drug) -> approved(technology,drug))",
        "natural": "If the drug is not profitable, then the technology for the drug is approved."
      },
      {
        "id": "Rule76",
        "formal": "(¬G → ¬A8)",
        "prover9_expression": "(-profitable(drug) -> -clinical_trial_completed(drug))",
        "natural": "If the drug is not profitable, then the clinical trial for the drug is not completed."
      }
    ],
    "facts": [
      {
        "id": "Fact1",
        "formal": "A2",
        "prover9_expression": "submitted(application,regulatory_agency)",
        "natural": "An application is submitted to the regulatory agency."
      },
      {
        "id": "Fact2",
        "formal": "A56",
        "prover9_expression": "patent_filing(drug)",
        "natural": "A patent is filed for the drug."
      },
      {
        "id": "Fact3",
        "formal": "A57",
        "prover9_expression": "patent_granted(drug)",
        "natural": "A patent is granted for the drug."
      },
      {
        "id": "Fact4",
        "formal": "¬A15",
        "prover9_expression": "-market_withdrawal(drug)",
        "natural": "It is not the case that the drug undergoes market withdrawal."
      },
      {
        "id": "Fact5",
        "formal": "¬A29",
        "prover9_expression": "-legal_distribution(drug)",
        "natural": "It is not the case that the drug is distributed legally."
      },
      {
        "id": "Fact6",
        "formal": "¬A31",
        "prover9_expression": "-full_approval(drug)",
        "natural": "It is not the case that the drug receives full approval."
      },
      {
        "id": "Fact7",
        "formal": "¬A36",
        "prover9_expression": "-compliance_maintained(company)",
        "natural": "It is not the case that the company maintains compliance."
      },
      {
        "id": "Fact8",
        "formal": "¬A39",
        "prover9_expression": "-orphan_drug_status(drug)",
        "natural": "It is not the case that the drug has orphan drug status."
      },
      {
        "id": "Fact9",
        "formal": "¬A42",
        "prover9_expression": "-combination_therapy(drug)",
        "natural": "It is not the case that the drug is a combination therapy."
      },
      {
        "id": "Fact10",
        "formal": "¬A48",
        "prover9_expression": "-risk_management_plan(drug)",
        "natural": "It is not the case that the drug has a risk management plan."
      },
      {
        "id": "Fact11",
        "formal": "¬A49",
        "prover9_expression": "-black_box_warning(drug)",
        "natural": "It is not the case that the drug has a black box warning."
      },
      {
        "id": "Fact12",
        "formal": "¬A50",
        "prover9_expression": "-patient_assistance_program(drug)",
        "natural": "It is not the case that the drug has a patient assistance program."
      },
      {
        "id": "Fact13",
        "formal": "¬A52",
        "prover9_expression": "-value_based_pricing(drug)",
        "natural": "It is not the case that the drug uses value-based pricing."
      },
      {
        "id": "Fact14",
        "formal": "¬A55",
        "prover9_expression": "-market_exclusivity(drug)",
        "natural": "It is not the case that the drug has market exclusivity."
      },
      {
        "id": "Fact15",
        "formal": "¬A61",
        "prover9_expression": "-formulary_inclusion(drug)",
        "natural": "It is not the case that the drug is included in a formulary."
      },
      {
        "id": "Fact16",
        "formal": "¬A77",
        "prover9_expression": "-temperature_excursion(drug)",
        "natural": "It is not the case that the drug experiences a temperature excursion."
      },
      {
        "id": "Fact17",
        "formal": "¬A80",
        "prover9_expression": "-batch_testing(drug)",
        "natural": "It is not the case that the drug undergoes batch testing."
      },
      {
        "id": "Fact18",
        "formal": "¬A81",
        "prover9_expression": "-stability_study(drug)",
        "natural": "It is not the case that the drug undergoes a stability study."
      }
    ]
  },
  "target": {
    "formal": "G",
    "prover9": "G",
    "prover9_expression": "profitable(drug)",
    "natural": "The drug is profitable."
  },
  "solutions": [
    {
      "id": 1,
      "family_id": 1,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "RAA",
          "premises_used": [
            "(-A6 -> A7)",
            "(-A6 -> -A7)"
          ],
          "conclusion": "A6",
          "natural": "The drug has patent protection."
        },
        {
          "step_number": 2,
          "rule_applied": "MP",
          "premises_used": [
            "(A6 -> (A5 -> (A3 -> (-G -> -A1))))",
            "A6"
          ],
          "conclusion": "(A5 -> (A3 -> (-G -> -A1)))",
          "natural": "If the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 3,
          "rule_applied": "DE",
          "premises_used": [
            "(A4 | A5)",
            "(A4 -> (A3 -> (-G -> -A1)))",
            "(A5 -> (A3 -> (-G -> -A1)))"
          ],
          "conclusion": "(A3 -> (-G -> -A1))",
          "natural": "Provided that the application is reviewed by the regulatory agency, if the drug is not profitable, then the technology for the drug is not approved."
        },
        {
          "step_number": 4,
          "rule_applied": "HS",
          "premises_used": [
            "(A2 -> A3)",
            "(A3 -> (-G -> -A1))"
          ],
          "conclusion": "(A2 -> (-G -> -A1))",
          "natural": "If an application is submitted to the regulatory agency, then if the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 5,
          "rule_applied": "MP",
          "premises_used": [
            "(A2 -> (-G -> -A1))",
            "A2"
          ],
          "conclusion": "(-G -> -A1)",
          "natural": "Provided that the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 6,
          "rule_applied": "RAA",
          "premises_used": [
            "(-G -> A1)",
            "(-G -> -A1)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 2,
      "family_id": 2,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A15 | (A14 -> -A11))",
            "-A15"
          ],
          "conclusion": "(A14 -> -A11)",
          "natural": "If a recall is issued for the drug, then a manufacturing issue with the drug does not hold."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A13 -> A14)",
            "(A14 -> -A11)"
          ],
          "conclusion": "(A13 -> -A11)",
          "natural": "If there is a quality control failure for the drug, then it is not the case that there is a manufacturing issue with the drug."
        },
        {
          "step_number": 3,
          "rule_applied": "DE",
          "premises_used": [
            "(A12 | A13)",
            "(A12 -> -A11)",
            "(A13 -> -A11)"
          ],
          "conclusion": "-A11",
          "natural": "It is not the case that there is a manufacturing issue with the drug."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            "(A11 | (A9 | A10))",
            "-A11"
          ],
          "conclusion": "(A9 | A10)",
          "natural": "Either the drug receives fast track approval or the drug is designated as a breakthrough therapy."
        },
        {
          "step_number": 5,
          "rule_applied": "DE",
          "premises_used": [
            "(A9 | A10)",
            "(A9 -> (-G -> A8))",
            "(A10 -> (-G -> A8))"
          ],
          "conclusion": "(-G -> A8)",
          "natural": "Under the condition that the drug is not profitable, the clinical trial for the drug is completed."
        },
        {
          "step_number": 6,
          "rule_applied": "RAA",
          "premises_used": [
            "(-G -> A8)",
            "(-G -> -A8)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 3,
      "family_id": 3,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "HS",
          "premises_used": [
            "(A21 -> A23)",
            "(A23 -> A22)"
          ],
          "conclusion": "(A21 -> A22)",
          "natural": "Whenever the drug receives regulatory approval, the drug is launched on the market."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A21 -> A22)",
            "(A22 -> (A19 -> A17))"
          ],
          "conclusion": "(A21 -> (A19 -> A17))",
          "natural": "If the drug receives regulatory approval, then provided that the drug receives private equity investment, the drug receives venture capital funding."
        },
        {
          "step_number": 3,
          "rule_applied": "DE",
          "premises_used": [
            "(A20 | A21)",
            "(A20 -> (A19 -> A17))",
            "(A21 -> (A19 -> A17))"
          ],
          "conclusion": "(A19 -> A17)",
          "natural": "Under the condition that the drug receives private equity investment, the drug receives venture capital funding."
        },
        {
          "step_number": 4,
          "rule_applied": "CD",
          "premises_used": [
            "(A18 -> A16)",
            "(A19 -> A17)",
            "(A18 | A19)"
          ],
          "conclusion": "(A16 | A17)",
          "natural": "Either the company makes a financial investment in the drug or the drug receives venture capital funding."
        },
        {
          "step_number": 5,
          "rule_applied": "DE",
          "premises_used": [
            "(A16 | A17)",
            "(A16 -> G)",
            "(A17 -> G)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 4,
      "family_id": 4,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A29 | -A28)",
            "-A29"
          ],
          "conclusion": "-A28",
          "natural": "It is not the case that the drug is distributed illegally."
        },
        {
          "step_number": 2,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A26 -> A27) -> A28)",
            "-A28"
          ],
          "conclusion": "(A26 -> A27)",
          "natural": "If the drug is a counterfeit product, then the drug is an authentic product."
        },
        {
          "step_number": 3,
          "rule_applied": "RAA",
          "premises_used": [
            "(A26 -> A27)",
            "(A26 -> -A27)"
          ],
          "conclusion": "-A26",
          "natural": "It is not the case that the drug is a counterfeit product."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            "(A26 | (A24 -> G))",
            "-A26"
          ],
          "conclusion": "(A24 -> G)",
          "natural": "Given that the drug uses blockchain tracking, the drug is profitable."
        },
        {
          "step_number": 5,
          "rule_applied": "DE",
          "premises_used": [
            "(A24 | A25)",
            "(A24 -> G)",
            "(A25 -> G)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 5,
      "family_id": 1,
      "path_type": "branch",
      "branch_from": 4,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A36 | -A35)",
            "-A36"
          ],
          "conclusion": "-A35",
          "natural": "It is not the case that the company commits a regulatory violation."
        },
        {
          "step_number": 2,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A33 -> A32) -> A35)",
            "-A35"
          ],
          "conclusion": "(A33 -> A32)",
          "natural": "Whenever the company undergoes an internal audit, the drug has a compliance certificate."
        },
        {
          "step_number": 3,
          "rule_applied": "DE",
          "premises_used": [
            "(A33 | A34)",
            "(A33 -> A32)",
            "(A34 -> A32)"
          ],
          "conclusion": "A32",
          "natural": "The drug has a compliance certificate."
        },
        {
          "step_number": 4,
          "rule_applied": "MP",
          "premises_used": [
            "(A32 -> (A31 | -A30))",
            "A32"
          ],
          "conclusion": "(A31 | -A30)",
          "natural": "Either the drug receives full approval or it is not the case that the drug receives conditional approval."
        },
        {
          "step_number": 5,
          "rule_applied": "DS",
          "premises_used": [
            "(A31 | -A30)",
            "-A31"
          ],
          "conclusion": "-A30",
          "natural": "It is not the case that the drug receives conditional approval."
        },
        {
          "step_number": 6,
          "rule_applied": "MT",
          "premises_used": [
            "(-(-G -> -A1) -> A30)",
            "-A30"
          ],
          "conclusion": "(-G -> -A1)",
          "natural": "Provided that the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 7,
          "rule_applied": "RAA",
          "premises_used": [
            "(-G -> A1)",
            "(-G -> -A1)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 6,
      "family_id": 1,
      "path_type": "branch",
      "branch_from": 1,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A42 | (A41 -> (A39 | (A37 -> (A5 -> (A3 -> (-G -> -A1)))))))",
            "-A42"
          ],
          "conclusion": "(A41 -> (A39 | (A37 -> (A5 -> (A3 -> (-G -> -A1))))))",
          "natural": "Provided that the drug has a common disease indication, either the drug has orphan drug status, or if the drug undergoes an accelerated review, then under the condition that the drug meets safety standards, whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 2,
          "rule_applied": "DE",
          "premises_used": [
            "(A40 | A41)",
            "(A40 -> (A39 | (A37 -> (A5 -> (A3 -> (-G -> -A1))))))",
            "(A41 -> (A39 | (A37 -> (A5 -> (A3 -> (-G -> -A1))))))"
          ],
          "conclusion": "(A39 | (A37 -> (A5 -> (A3 -> (-G -> -A1)))))",
          "natural": "Either the drug has orphan drug status, or if the drug undergoes an accelerated review, then under the condition that the drug meets safety standards, provided that the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 3,
          "rule_applied": "DS",
          "premises_used": [
            "(A39 | (A37 -> (A5 -> (A3 -> (-G -> -A1)))))",
            "-A39"
          ],
          "conclusion": "(A37 -> (A5 -> (A3 -> (-G -> -A1))))",
          "natural": "If the drug undergoes an accelerated review, then provided that the drug meets safety standards, if the application is reviewed by the regulatory agency, then if the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A37 | A38)",
            "(A37 -> (A5 -> (A3 -> (-G -> -A1))))",
            "(A38 -> (A5 -> (A3 -> (-G -> -A1))))"
          ],
          "conclusion": "(A5 -> (A3 -> (-G -> -A1)))",
          "natural": "If the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 5,
          "rule_applied": "DE",
          "premises_used": [
            "(A4 | A5)",
            "(A4 -> (A3 -> (-G -> -A1)))",
            "(A5 -> (A3 -> (-G -> -A1)))"
          ],
          "conclusion": "(A3 -> (-G -> -A1))",
          "natural": "Provided that the application is reviewed by the regulatory agency, if the drug is not profitable, then the technology for the drug is not approved."
        },
        {
          "step_number": 6,
          "rule_applied": "HS",
          "premises_used": [
            "(A2 -> A3)",
            "(A3 -> (-G -> -A1))"
          ],
          "conclusion": "(A2 -> (-G -> -A1))",
          "natural": "If an application is submitted to the regulatory agency, then if the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 7,
          "rule_applied": "MP",
          "premises_used": [
            "(A2 -> (-G -> -A1))",
            "A2"
          ],
          "conclusion": "(-G -> -A1)",
          "natural": "Provided that the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 8,
          "rule_applied": "RAA",
          "premises_used": [
            "(-G -> A1)",
            "(-G -> -A1)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 7,
      "family_id": 1,
      "path_type": "branch",
      "branch_from": 1,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MT",
          "premises_used": [
            "(-(-(A47 -> (A43 -> -A44)) -> A48) -> A49)",
            "-A49"
          ],
          "conclusion": "(-(A47 -> (A43 -> -A44)) -> A48)",
          "natural": "Given that it is not the case that if the drug undergoes safety monitoring then if the drug has a drug interaction issue then the drug does not have adverse events, the drug has a risk management plan."
        },
        {
          "step_number": 2,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A47 -> (A43 -> -A44)) -> A48)",
            "-A48"
          ],
          "conclusion": "(A47 -> (A43 -> -A44))",
          "natural": "Provided that the drug undergoes safety monitoring, if the drug has a drug interaction issue, then the drug does not have adverse events."
        },
        {
          "step_number": 3,
          "rule_applied": "HS",
          "premises_used": [
            "(A45 -> A47)",
            "(A47 -> (A43 -> -A44))"
          ],
          "conclusion": "(A45 -> (A43 -> -A44))",
          "natural": "Provided that the drug undergoes post-market surveillance, if the drug has a drug interaction issue, then it is not the case that the drug has adverse events."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A45 | A46)",
            "(A45 -> (A43 -> -A44))",
            "(A46 -> (A43 -> -A44))"
          ],
          "conclusion": "(A43 -> -A44)",
          "natural": "Under the condition that the drug has a drug interaction issue, the drug does not have adverse events."
        },
        {
          "step_number": 5,
          "rule_applied": "RAA",
          "premises_used": [
            "(A43 -> A44)",
            "(A43 -> -A44)"
          ],
          "conclusion": "-A43",
          "natural": "It is not the case that the drug has a drug interaction issue."
        },
        {
          "step_number": 6,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A5 -> (A3 -> (-G -> -A1))) -> A43)",
            "-A43"
          ],
          "conclusion": "(A5 -> (A3 -> (-G -> -A1)))",
          "natural": "If the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 7,
          "rule_applied": "DE",
          "premises_used": [
            "(A4 | A5)",
            "(A4 -> (A3 -> (-G -> -A1)))",
            "(A5 -> (A3 -> (-G -> -A1)))"
          ],
          "conclusion": "(A3 -> (-G -> -A1))",
          "natural": "Provided that the application is reviewed by the regulatory agency, if the drug is not profitable, then the technology for the drug is not approved."
        },
        {
          "step_number": 8,
          "rule_applied": "HS",
          "premises_used": [
            "(A2 -> A3)",
            "(A3 -> (-G -> -A1))"
          ],
          "conclusion": "(A2 -> (-G -> -A1))",
          "natural": "If an application is submitted to the regulatory agency, then if the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 9,
          "rule_applied": "MP",
          "premises_used": [
            "(A2 -> (-G -> -A1))",
            "A2"
          ],
          "conclusion": "(-G -> -A1)",
          "natural": "Provided that the drug is not profitable, the technology for the drug is not approved."
        },
        {
          "step_number": 10,
          "rule_applied": "RAA",
          "premises_used": [
            "(-G -> A1)",
            "(-G -> -A1)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 8,
      "family_id": 3,
      "path_type": "branch",
      "branch_from": 2,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DE",
          "premises_used": [
            "(A53 | A54)",
            "(A53 -> (A52 | (-(A50 | (A19 -> A17)) -> A51)))",
            "(A54 -> (A52 | (-(A50 | (A19 -> A17)) -> A51)))"
          ],
          "conclusion": "(A52 | (-(A50 | (A19 -> A17)) -> A51))",
          "natural": "Either the drug uses value-based pricing, or if it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, then the drug is under price control."
        },
        {
          "step_number": 2,
          "rule_applied": "DS",
          "premises_used": [
            "(A52 | (-(A50 | (A19 -> A17)) -> A51))",
            "-A52"
          ],
          "conclusion": "(-(A50 | (A19 -> A17)) -> A51)",
          "natural": "If it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, then the drug is under price control."
        },
        {
          "step_number": 3,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(A50 | (A19 -> A17)) -> A51)",
            "(-(A50 | (A19 -> A17)) -> -A51)"
          ],
          "conclusion": "(A50 | (A19 -> A17))",
          "natural": "Either the drug has a patient assistance program or if the drug receives private equity investment, then the drug receives venture capital funding."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            "(A50 | (A19 -> A17))",
            "-A50"
          ],
          "conclusion": "(A19 -> A17)",
          "natural": "Under the condition that the drug receives private equity investment, the drug receives venture capital funding."
        },
        {
          "step_number": 5,
          "rule_applied": "CD",
          "premises_used": [
            "(A18 -> A16)",
            "(A19 -> A17)",
            "(A18 | A19)"
          ],
          "conclusion": "(A16 | A17)",
          "natural": "Either the company makes a financial investment in the drug or the drug receives venture capital funding."
        },
        {
          "step_number": 6,
          "rule_applied": "DE",
          "premises_used": [
            "(A16 | A17)",
            "(A16 -> G)",
            "(A17 -> G)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 9,
      "family_id": 3,
      "path_type": "branch",
      "branch_from": 0,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "HS",
          "premises_used": [
            "(A58 -> A59)",
            "(A59 -> (A56 -> (-(A21 -> A22) -> A55)))"
          ],
          "conclusion": "(A58 -> (A56 -> (-(A21 -> A22) -> A55)))",
          "natural": "Provided that the drug has patent exclusivity, if a patent is filed for the drug, then given that it is not the case that if the drug receives regulatory approval then the drug is launched on the market, the drug has market exclusivity."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A57 -> A58)",
            "(A58 -> (A56 -> (-(A21 -> A22) -> A55)))"
          ],
          "conclusion": "(A57 -> (A56 -> (-(A21 -> A22) -> A55)))",
          "natural": "If a patent is granted for the drug, then whenever a patent is filed for the drug, if it is not the case that if the drug receives regulatory approval then the drug is launched on the market, then the drug has market exclusivity."
        },
        {
          "step_number": 3,
          "rule_applied": "MP",
          "premises_used": [
            "(A57 -> (A56 -> (-(A21 -> A22) -> A55)))",
            "A57"
          ],
          "conclusion": "(A56 -> (-(A21 -> A22) -> A55))",
          "natural": "Provided that a patent is filed for the drug, if it is not the case that if the drug receives regulatory approval then the drug is launched on the market, then the drug has market exclusivity."
        },
        {
          "step_number": 4,
          "rule_applied": "MP",
          "premises_used": [
            "(A56 -> (-(A21 -> A22) -> A55))",
            "A56"
          ],
          "conclusion": "(-(A21 -> A22) -> A55)",
          "natural": "If it is not the case that if the drug receives regulatory approval then the drug is launched on the market, then the drug has market exclusivity."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A21 -> A22) -> A55)",
            "-A55"
          ],
          "conclusion": "(A21 -> A22)",
          "natural": "Whenever the drug receives regulatory approval, the drug is launched on the market."
        },
        {
          "step_number": 6,
          "rule_applied": "HS",
          "premises_used": [
            "(A21 -> A22)",
            "(A22 -> (A19 -> A17))"
          ],
          "conclusion": "(A21 -> (A19 -> A17))",
          "natural": "If the drug receives regulatory approval, then provided that the drug receives private equity investment, the drug receives venture capital funding."
        },
        {
          "step_number": 7,
          "rule_applied": "DE",
          "premises_used": [
            "(A20 | A21)",
            "(A20 -> (A19 -> A17))",
            "(A21 -> (A19 -> A17))"
          ],
          "conclusion": "(A19 -> A17)",
          "natural": "Under the condition that the drug receives private equity investment, the drug receives venture capital funding."
        },
        {
          "step_number": 8,
          "rule_applied": "CD",
          "premises_used": [
            "(A18 -> A16)",
            "(A19 -> A17)",
            "(A18 | A19)"
          ],
          "conclusion": "(A16 | A17)",
          "natural": "Either the company makes a financial investment in the drug or the drug receives venture capital funding."
        },
        {
          "step_number": 9,
          "rule_applied": "DE",
          "premises_used": [
            "(A16 | A17)",
            "(A16 -> G)",
            "(A17 -> G)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 10,
      "family_id": 3,
      "path_type": "branch",
      "branch_from": 1,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(A61 | (A60 -> (A19 -> A17))) -> A62)",
            "(-(A61 | (A60 -> (A19 -> A17))) -> -A62)"
          ],
          "conclusion": "(A61 | (A60 -> (A19 -> A17)))",
          "natural": "Either the drug is included in a formulary or if the drug receives reimbursement approval, then if the drug receives private equity investment, the drug receives venture capital funding."
        },
        {
          "step_number": 2,
          "rule_applied": "DS",
          "premises_used": [
            "(A61 | (A60 -> (A19 -> A17)))",
            "-A61"
          ],
          "conclusion": "(A60 -> (A19 -> A17))",
          "natural": "If the drug receives reimbursement approval, then provided that the drug receives private equity investment, the drug receives venture capital funding."
        },
        {
          "step_number": 3,
          "rule_applied": "HS",
          "premises_used": [
            "(A21 -> A60)",
            "(A60 -> (A19 -> A17))"
          ],
          "conclusion": "(A21 -> (A19 -> A17))",
          "natural": "If the drug receives regulatory approval, then provided that the drug receives private equity investment, the drug receives venture capital funding."
        },
        {
          "step_number": 4,
          "rule_applied": "DE",
          "premises_used": [
            "(A20 | A21)",
            "(A20 -> (A19 -> A17))",
            "(A21 -> (A19 -> A17))"
          ],
          "conclusion": "(A19 -> A17)",
          "natural": "Under the condition that the drug receives private equity investment, the drug receives venture capital funding."
        },
        {
          "step_number": 5,
          "rule_applied": "CD",
          "premises_used": [
            "(A18 -> A16)",
            "(A19 -> A17)",
            "(A18 | A19)"
          ],
          "conclusion": "(A16 | A17)",
          "natural": "Either the company makes a financial investment in the drug or the drug receives venture capital funding."
        },
        {
          "step_number": 6,
          "rule_applied": "DE",
          "premises_used": [
            "(A16 | A17)",
            "(A16 -> G)",
            "(A17 -> G)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 11,
      "family_id": 4,
      "path_type": "branch",
      "branch_from": 2,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "HS",
          "premises_used": [
            "(A70 -> A71)",
            "(A71 -> -A69)"
          ],
          "conclusion": "(A70 -> -A69)",
          "natural": "If the drug is produced through manual production, then the drug is not produced through automated production."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A68 -> A70)",
            "(A70 -> -A69)"
          ],
          "conclusion": "(A68 -> -A69)",
          "natural": "Provided that a manufacturing process uses technology for the drug, it is not the case that the drug is produced through automated production."
        },
        {
          "step_number": 3,
          "rule_applied": "RAA",
          "premises_used": [
            "(A68 -> A69)",
            "(A68 -> -A69)"
          ],
          "conclusion": "-A68",
          "natural": "It is not the case that a manufacturing process uses technology for the drug."
        },
        {
          "step_number": 4,
          "rule_applied": "DS",
          "premises_used": [
            "(A68 | -A67)",
            "-A68"
          ],
          "conclusion": "-A67",
          "natural": "It is not the case that there is patent infringement for the drug."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A66 -> (A63 -> A64)) -> A67)",
            "-A67"
          ],
          "conclusion": "(A66 -> (A63 -> A64))",
          "natural": "Provided that there is a patent settlement for the drug, if the drug faces generic competition, then a biosimilar version of the drug is available."
        },
        {
          "step_number": 6,
          "rule_applied": "DE",
          "premises_used": [
            "(A65 | A66)",
            "(A65 -> (A63 -> A64))",
            "(A66 -> (A63 -> A64))"
          ],
          "conclusion": "(A63 -> A64)",
          "natural": "Provided that the drug faces generic competition, a biosimilar version of the drug is available."
        },
        {
          "step_number": 7,
          "rule_applied": "RAA",
          "premises_used": [
            "(A63 -> A64)",
            "(A63 -> -A64)"
          ],
          "conclusion": "-A63",
          "natural": "It is not the case that the drug faces generic competition."
        },
        {
          "step_number": 8,
          "rule_applied": "MT",
          "premises_used": [
            "(A26 -> A63)",
            "-A63"
          ],
          "conclusion": "-A26",
          "natural": "It is not the case that the drug is a counterfeit product."
        },
        {
          "step_number": 9,
          "rule_applied": "DS",
          "premises_used": [
            "(A26 | (A24 -> G))",
            "-A26"
          ],
          "conclusion": "(A24 -> G)",
          "natural": "Given that the drug uses blockchain tracking, the drug is profitable."
        },
        {
          "step_number": 10,
          "rule_applied": "DE",
          "premises_used": [
            "(A24 | A25)",
            "(A24 -> G)",
            "(A25 -> G)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 12,
      "family_id": 4,
      "path_type": "branch",
      "branch_from": 0,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DE",
          "premises_used": [
            "(A74 | A75)",
            "(A74 -> -A73)",
            "(A75 -> -A73)"
          ],
          "conclusion": "-A73",
          "natural": "It is not the case that production of the drug is delayed."
        },
        {
          "step_number": 2,
          "rule_applied": "MT",
          "premises_used": [
            "(A72 -> A73)",
            "-A73"
          ],
          "conclusion": "-A72",
          "natural": "It is not the case that the drug experiences a supply chain disruption."
        },
        {
          "step_number": 3,
          "rule_applied": "MT",
          "premises_used": [
            "(A28 -> A72)",
            "-A72"
          ],
          "conclusion": "-A28",
          "natural": "It is not the case that the drug is distributed illegally."
        },
        {
          "step_number": 4,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A26 -> A27) -> A28)",
            "-A28"
          ],
          "conclusion": "(A26 -> A27)",
          "natural": "If the drug is a counterfeit product, then the drug is an authentic product."
        },
        {
          "step_number": 5,
          "rule_applied": "RAA",
          "premises_used": [
            "(A26 -> A27)",
            "(A26 -> -A27)"
          ],
          "conclusion": "-A26",
          "natural": "It is not the case that the drug is a counterfeit product."
        },
        {
          "step_number": 6,
          "rule_applied": "DS",
          "premises_used": [
            "(A26 | (A24 -> G))",
            "-A26"
          ],
          "conclusion": "(A24 -> G)",
          "natural": "Given that the drug uses blockchain tracking, the drug is profitable."
        },
        {
          "step_number": 7,
          "rule_applied": "DE",
          "premises_used": [
            "(A24 | A25)",
            "(A24 -> G)",
            "(A25 -> G)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    },
    {
      "id": 13,
      "family_id": 4,
      "path_type": "branch",
      "branch_from": 0,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "DS",
          "premises_used": [
            "(A81 | (A80 | -A79))",
            "-A81"
          ],
          "conclusion": "(A80 | -A79)",
          "natural": "Either the drug undergoes batch testing or the drug does not undergo quality assurance."
        },
        {
          "step_number": 2,
          "rule_applied": "DS",
          "premises_used": [
            "(A80 | -A79)",
            "-A80"
          ],
          "conclusion": "-A79",
          "natural": "It is not the case that the drug undergoes quality assurance."
        },
        {
          "step_number": 3,
          "rule_applied": "DS",
          "premises_used": [
            "(A79 | (A78 -> A77))",
            "-A79"
          ],
          "conclusion": "(A78 -> A77)",
          "natural": "Under the condition that the drug has a humidity issue, the drug experiences a temperature excursion."
        },
        {
          "step_number": 4,
          "rule_applied": "HS",
          "premises_used": [
            "(A76 -> A78)",
            "(A78 -> A77)"
          ],
          "conclusion": "(A76 -> A77)",
          "natural": "Provided that there is a storage violation for the drug, the drug experiences a temperature excursion."
        },
        {
          "step_number": 5,
          "rule_applied": "MT",
          "premises_used": [
            "(A76 -> A77)",
            "-A77"
          ],
          "conclusion": "-A76",
          "natural": "It is not the case that there is a storage violation for the drug."
        },
        {
          "step_number": 6,
          "rule_applied": "MT",
          "premises_used": [
            "(A28 -> A76)",
            "-A76"
          ],
          "conclusion": "-A28",
          "natural": "It is not the case that the drug is distributed illegally."
        },
        {
          "step_number": 7,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A26 -> A27) -> A28)",
            "-A28"
          ],
          "conclusion": "(A26 -> A27)",
          "natural": "If the drug is a counterfeit product, then the drug is an authentic product."
        },
        {
          "step_number": 8,
          "rule_applied": "RAA",
          "premises_used": [
            "(A26 -> A27)",
            "(A26 -> -A27)"
          ],
          "conclusion": "-A26",
          "natural": "It is not the case that the drug is a counterfeit product."
        },
        {
          "step_number": 9,
          "rule_applied": "DS",
          "premises_used": [
            "(A26 | (A24 -> G))",
            "-A26"
          ],
          "conclusion": "(A24 -> G)",
          "natural": "Given that the drug uses blockchain tracking, the drug is profitable."
        },
        {
          "step_number": 10,
          "rule_applied": "DE",
          "premises_used": [
            "(A24 | A25)",
            "(A24 -> G)",
            "(A25 -> G)"
          ],
          "conclusion": "G",
          "natural": "The drug is profitable."
        }
      ]
    }
  ],
  "translations": {
    "domain_theme": "Pharmaceutical Regulatory Compliance",
    "atomic_facts": {
      "A1": "approved(technology,drug)",
      "A2": "submitted(application,regulatory_agency)",
      "A3": "reviewed(application,regulatory_agency)",
      "A4": "requires_clinical_trials(drug)",
      "A5": "meets_safety_standards(drug)",
      "A6": "has_patent_protection(drug)",
      "A7": "generic_version_available(drug)",
      "A8": "clinical_trial_completed(drug)",
      "A9": "fast_track_approval(drug)",
      "A10": "breakthrough_therapy(drug)",
      "A11": "manufacturing_issue(drug)",
      "A12": "contamination_found(drug)",
      "A13": "quality_control_failure(drug)",
      "A14": "recall_issued(drug)",
      "A15": "market_withdrawal(drug)",
      "A16": "financial_investment(company,drug)",
      "A17": "venture_capital_funding(drug)",
      "A18": "initial_public_offering(company)",
      "A19": "private_equity_investment(drug)",
      "A20": "successful_phase3_trial(drug)",
      "A21": "regulatory_approval(drug)",
      "A22": "market_launch(drug)",
      "A23": "marketing_campaign(drug)",
      "A24": "blockchain_tracking(drug)",
      "A25": "traditional_tracking(drug)",
      "A26": "counterfeit_product(drug)",
      "A27": "authentic_product(drug)",
      "A28": "illegal_distribution(drug)",
      "A29": "legal_distribution(drug)",
      "A30": "conditional_approval(drug)",
      "A31": "full_approval(drug)",
      "A32": "compliance_certificate(drug)",
      "A33": "internal_audit(company)",
      "A34": "external_audit(company)",
      "A35": "regulatory_violation(company)",
      "A36": "compliance_maintained(company)",
      "A37": "accelerated_review(drug)",
      "A38": "standard_review(drug)",
      "A39": "orphan_drug_status(drug)",
      "A40": "rare_disease_indication(drug)",
      "A41": "common_disease_indication(drug)",
      "A42": "combination_therapy(drug)",
      "A43": "drug_interaction_issue(drug)",
      "A44": "adverse_events(drug)",
      "A45": "post_market_surveillance(drug)",
      "A46": "pre_market_testing(drug)",
      "A47": "safety_monitoring(drug)",
      "A48": "risk_management_plan(drug)",
      "A49": "black_box_warning(drug)",
      "A50": "patient_assistance_program(drug)",
      "A51": "price_control(drug)",
      "A52": "value_based_pricing(drug)",
      "A53": "health_economics_study(drug)",
      "A54": "outcomes_research(drug)",
      "A55": "market_exclusivity(drug)",
      "A56": "patent_filing(drug)",
      "A57": "patent_granted(drug)",
      "A58": "patent_exclusivity(drug)",
      "A59": "patent_extension(drug)",
      "A60": "reimbursement_approval(drug)",
      "A61": "formulary_inclusion(drug)",
      "A62": "prior_authorization(drug)",
      "A63": "generic_competition(drug)",
      "A64": "biosimilar_version(drug)",
      "A65": "patent_litigation(drug)",
      "A66": "patent_settlement(drug)",
      "A67": "patent_infringement(drug)",
      "A68": "manufacturing_process(technology,drug)",
      "A69": "automated_production(drug)",
      "A70": "manual_production(drug)",
      "A71": "hybrid_production(drug)",
      "A72": "supply_chain_disruption(drug)",
      "A73": "production_delayed(drug)",
      "A74": "alternative_supplier(drug)",
      "A75": "backup_manufacturer(drug)",
      "A76": "storage_violation(drug)",
      "A77": "temperature_excursion(drug)",
      "A78": "humidity_issue(drug)",
      "A79": "quality_assurance(drug)",
      "A80": "batch_testing(drug)",
      "A81": "stability_study(drug)",
      "G": "profitable(drug)"
    },
    "natural_facts": {
      "A1": "The technology for the drug is approved.",
      "A2": "An application is submitted to the regulatory agency.",
      "A3": "The application is reviewed by the regulatory agency.",
      "A4": "Clinical trials are required for the drug.",
      "A5": "The drug meets safety standards.",
      "A6": "The drug has patent protection.",
      "A7": "A generic version of the drug is available.",
      "A8": "The clinical trial for the drug is completed.",
      "A9": "The drug receives fast track approval.",
      "A10": "The drug is designated as a breakthrough therapy.",
      "A11": "There is a manufacturing issue with the drug.",
      "A12": "Contamination is found in the drug.",
      "A13": "There is a quality control failure for the drug.",
      "A14": "A recall is issued for the drug.",
      "A15": "The drug undergoes market withdrawal.",
      "A16": "The company makes a financial investment in the drug.",
      "A17": "The drug receives venture capital funding.",
      "A18": "The company conducts an initial public offering.",
      "A19": "The drug receives private equity investment.",
      "A20": "The drug has a successful phase 3 trial.",
      "A21": "The drug receives regulatory approval.",
      "A22": "The drug is launched on the market.",
      "A23": "A marketing campaign is conducted for the drug.",
      "A24": "The drug uses blockchain tracking.",
      "A25": "The drug uses traditional tracking.",
      "A26": "The drug is a counterfeit product.",
      "A27": "The drug is an authentic product.",
      "A28": "The drug is distributed illegally.",
      "A29": "The drug is distributed legally.",
      "A30": "The drug receives conditional approval.",
      "A31": "The drug receives full approval.",
      "A32": "The drug has a compliance certificate.",
      "A33": "The company undergoes an internal audit.",
      "A34": "The company undergoes an external audit.",
      "A35": "The company commits a regulatory violation.",
      "A36": "The company maintains compliance.",
      "A37": "The drug undergoes an accelerated review.",
      "A38": "The drug undergoes a standard review.",
      "A39": "The drug has orphan drug status.",
      "A40": "The drug has a rare disease indication.",
      "A41": "The drug has a common disease indication.",
      "A42": "The drug is a combination therapy.",
      "A43": "The drug has a drug interaction issue.",
      "A44": "The drug has adverse events.",
      "A45": "The drug undergoes post-market surveillance.",
      "A46": "The drug undergoes pre-market testing.",
      "A47": "The drug undergoes safety monitoring.",
      "A48": "The drug has a risk management plan.",
      "A49": "The drug has a black box warning.",
      "A50": "The drug has a patient assistance program.",
      "A51": "The drug is under price control.",
      "A52": "The drug uses value-based pricing.",
      "A53": "A health economics study is conducted for the drug.",
      "A54": "Outcomes research is conducted for the drug.",
      "A55": "The drug has market exclusivity.",
      "A56": "A patent is filed for the drug.",
      "A57": "A patent is granted for the drug.",
      "A58": "The drug has patent exclusivity.",
      "A59": "The drug receives a patent extension.",
      "A60": "The drug receives reimbursement approval.",
      "A61": "The drug is included in a formulary.",
      "A62": "The drug requires prior authorization.",
      "A63": "The drug faces generic competition.",
      "A64": "A biosimilar version of the drug is available.",
      "A65": "There is patent litigation for the drug.",
      "A66": "There is a patent settlement for the drug.",
      "A67": "There is patent infringement for the drug.",
      "A68": "A manufacturing process uses technology for the drug.",
      "A69": "The drug is produced through automated production.",
      "A70": "The drug is produced through manual production.",
      "A71": "The drug is produced through hybrid production.",
      "A72": "The drug experiences a supply chain disruption.",
      "A73": "Production of the drug is delayed.",
      "A74": "The drug has an alternative supplier.",
      "A75": "The drug has a backup manufacturer.",
      "A76": "There is a storage violation for the drug.",
      "A77": "The drug experiences a temperature excursion.",
      "A78": "The drug has a humidity issue.",
      "A79": "The drug undergoes quality assurance.",
      "A80": "The drug undergoes batch testing.",
      "A81": "The drug undergoes a stability study.",
      "G": "The drug is profitable."
    },
    "prover9_expressions": [
      "(breakthrough_therapy(drug) -> (-profitable(drug) -> clinical_trial_completed(drug)))",
      "(manufacturing_issue(drug) | (fast_track_approval(drug) | breakthrough_therapy(drug)))",
      "(contamination_found(drug) -> -manufacturing_issue(drug))",
      "(contamination_found(drug) | quality_control_failure(drug))",
      "(quality_control_failure(drug) -> recall_issued(drug))",
      "(quality_control_failure(drug) -> -manufacturing_issue(drug))",
      "(recall_issued(drug) -> -manufacturing_issue(drug))",
      "(market_withdrawal(drug) | (recall_issued(drug) -> -manufacturing_issue(drug)))",
      "(financial_investment(company,drug) -> profitable(drug))",
      "(financial_investment(company,drug) | venture_capital_funding(drug))",
      "(venture_capital_funding(drug) -> profitable(drug))",
      "(initial_public_offering(company) -> financial_investment(company,drug))",
      "(initial_public_offering(company) | private_equity_investment(drug))",
      "(private_equity_investment(drug) -> venture_capital_funding(drug))",
      "(submitted(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))",
      "(submitted(application,regulatory_agency) -> reviewed(application,regulatory_agency))",
      "(successful_phase3_trial(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))",
      "(successful_phase3_trial(drug) | regulatory_approval(drug))",
      "(regulatory_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))",
      "(regulatory_approval(drug) -> market_launch(drug))",
      "(regulatory_approval(drug) -> marketing_campaign(drug))",
      "(regulatory_approval(drug) -> reimbursement_approval(drug))",
      "(market_launch(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))",
      "(marketing_campaign(drug) -> market_launch(drug))",
      "(blockchain_tracking(drug) -> profitable(drug))",
      "(blockchain_tracking(drug) | traditional_tracking(drug))",
      "(traditional_tracking(drug) -> profitable(drug))",
      "(counterfeit_product(drug) -> authentic_product(drug))",
      "(counterfeit_product(drug) -> generic_competition(drug))",
      "(counterfeit_product(drug) -> -authentic_product(drug))",
      "(counterfeit_product(drug) | (blockchain_tracking(drug) -> profitable(drug)))",
      "(illegal_distribution(drug) -> supply_chain_disruption(drug))",
      "(illegal_distribution(drug) -> storage_violation(drug))",
      "(legal_distribution(drug) | -illegal_distribution(drug))",
      "(reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))",
      "(full_approval(drug) | -conditional_approval(drug))",
      "(compliance_certificate(drug) -> (full_approval(drug) | -conditional_approval(drug)))",
      "(internal_audit(company) -> compliance_certificate(drug))",
      "(internal_audit(company) | external_audit(company))",
      "(external_audit(company) -> compliance_certificate(drug))",
      "(compliance_maintained(company) | -regulatory_violation(company))",
      "(accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))",
      "(accelerated_review(drug) | standard_review(drug))",
      "(standard_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))",
      "(orphan_drug_status(drug) | (accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug))))))",
      "(requires_clinical_trials(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug))))",
      "(requires_clinical_trials(drug) | meets_safety_standards(drug))",
      "(rare_disease_indication(drug) -> (orphan_drug_status(drug) | (accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))))",
      "(rare_disease_indication(drug) | common_disease_indication(drug))",
      "(common_disease_indication(drug) -> (orphan_drug_status(drug) | (accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))))",
      "(combination_therapy(drug) | (common_disease_indication(drug) -> (orphan_drug_status(drug) | (accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug))))))))",
      "(drug_interaction_issue(drug) -> adverse_events(drug))",
      "(drug_interaction_issue(drug) -> -adverse_events(drug))",
      "(post_market_surveillance(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug)))",
      "(post_market_surveillance(drug) -> safety_monitoring(drug))",
      "(post_market_surveillance(drug) | pre_market_testing(drug))",
      "(pre_market_testing(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug)))",
      "(safety_monitoring(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug)))",
      "(meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug))))",
      "(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug)))",
      "(value_based_pricing(drug) | (-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> price_control(drug)))",
      "(health_economics_study(drug) -> (value_based_pricing(drug) | (-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> price_control(drug))))",
      "(health_economics_study(drug) | outcomes_research(drug))",
      "(outcomes_research(drug) -> (value_based_pricing(drug) | (-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> price_control(drug))))",
      "(patent_filing(drug) -> (-(regulatory_approval(drug) -> market_launch(drug)) -> market_exclusivity(drug)))",
      "(patent_granted(drug) -> (patent_filing(drug) -> (-(regulatory_approval(drug) -> market_launch(drug)) -> market_exclusivity(drug))))",
      "(patent_granted(drug) -> patent_exclusivity(drug))",
      "(patent_exclusivity(drug) -> (patent_filing(drug) -> (-(regulatory_approval(drug) -> market_launch(drug)) -> market_exclusivity(drug))))",
      "(patent_exclusivity(drug) -> patent_extension(drug))",
      "(patent_extension(drug) -> (patent_filing(drug) -> (-(regulatory_approval(drug) -> market_launch(drug)) -> market_exclusivity(drug))))",
      "(has_patent_protection(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))",
      "(reimbursement_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))",
      "(formulary_inclusion(drug) | (reimbursement_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug))))",
      "(generic_competition(drug) -> biosimilar_version(drug))",
      "(generic_competition(drug) -> -biosimilar_version(drug))",
      "(patent_litigation(drug) -> (generic_competition(drug) -> biosimilar_version(drug)))",
      "(patent_litigation(drug) | patent_settlement(drug))",
      "(patent_settlement(drug) -> (generic_competition(drug) -> biosimilar_version(drug)))",
      "(manufacturing_process(technology,drug) -> automated_production(drug))",
      "(manufacturing_process(technology,drug) -> manual_production(drug))",
      "(manufacturing_process(technology,drug) -> -automated_production(drug))",
      "(manufacturing_process(technology,drug) | -patent_infringement(drug))",
      "(manual_production(drug) -> hybrid_production(drug))",
      "(manual_production(drug) -> -automated_production(drug))",
      "(hybrid_production(drug) -> -automated_production(drug))",
      "(supply_chain_disruption(drug) -> production_delayed(drug))",
      "(alternative_supplier(drug) -> -production_delayed(drug))",
      "(alternative_supplier(drug) | backup_manufacturer(drug))",
      "(backup_manufacturer(drug) -> -production_delayed(drug))",
      "(storage_violation(drug) -> temperature_excursion(drug))",
      "(storage_violation(drug) -> humidity_issue(drug))",
      "(humidity_issue(drug) -> temperature_excursion(drug))",
      "(quality_assurance(drug) | (humidity_issue(drug) -> temperature_excursion(drug)))",
      "(batch_testing(drug) | -quality_assurance(drug))",
      "(stability_study(drug) | (batch_testing(drug) | -quality_assurance(drug)))",
      "(fast_track_approval(drug) -> (-profitable(drug) -> clinical_trial_completed(drug)))",
      "(fast_track_approval(drug) | breakthrough_therapy(drug))",
      "(-(regulatory_approval(drug) -> market_launch(drug)) -> market_exclusivity(drug))",
      "(-(counterfeit_product(drug) -> authentic_product(drug)) -> illegal_distribution(drug))",
      "(-(internal_audit(company) -> compliance_certificate(drug)) -> regulatory_violation(company))",
      "(-(safety_monitoring(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug))) -> risk_management_plan(drug))",
      "(-(meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))) -> drug_interaction_issue(drug))",
      "(-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> price_control(drug))",
      "(-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> -price_control(drug))",
      "(-(formulary_inclusion(drug) | (reimbursement_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))) -> prior_authorization(drug))",
      "(-(formulary_inclusion(drug) | (reimbursement_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))) -> -prior_authorization(drug))",
      "(-(patent_settlement(drug) -> (generic_competition(drug) -> biosimilar_version(drug))) -> patent_infringement(drug))",
      "(-(-(safety_monitoring(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug))) -> risk_management_plan(drug)) -> black_box_warning(drug))",
      "(-(-profitable(drug) -> -approved(technology,drug)) -> conditional_approval(drug))",
      "(-has_patent_protection(drug) -> generic_version_available(drug))",
      "(-has_patent_protection(drug) -> -generic_version_available(drug))",
      "(-profitable(drug) -> approved(technology,drug))",
      "(-profitable(drug) -> clinical_trial_completed(drug))",
      "(-profitable(drug) -> -approved(technology,drug))",
      "(-profitable(drug) -> -clinical_trial_completed(drug))",
      "submitted(application,regulatory_agency)",
      "compliance_certificate(drug)",
      "patent_filing(drug)",
      "patent_granted(drug)",
      "has_patent_protection(drug)",
      "profitable(drug)",
      "-manufacturing_issue(drug)",
      "-market_withdrawal(drug)",
      "-counterfeit_product(drug)",
      "-illegal_distribution(drug)",
      "-legal_distribution(drug)",
      "-conditional_approval(drug)",
      "-full_approval(drug)",
      "-regulatory_violation(company)",
      "-compliance_maintained(company)",
      "-orphan_drug_status(drug)",
      "-combination_therapy(drug)",
      "-drug_interaction_issue(drug)",
      "-risk_management_plan(drug)",
      "-black_box_warning(drug)",
      "-patient_assistance_program(drug)",
      "-value_based_pricing(drug)",
      "-market_exclusivity(drug)",
      "-formulary_inclusion(drug)",
      "-generic_competition(drug)",
      "-patent_infringement(drug)",
      "-manufacturing_process(technology,drug)",
      "-supply_chain_disruption(drug)",
      "-production_delayed(drug)",
      "-storage_violation(drug)",
      "-temperature_excursion(drug)",
      "-quality_assurance(drug)",
      "-batch_testing(drug)",
      "-stability_study(drug)"
    ],
    "natural_expressions": [
      "Provided that the drug is designated as a breakthrough therapy, if the drug is not profitable, then the clinical trial for the drug is completed.",
      "Either there is a manufacturing issue with the drug, or the drug receives fast track approval, or the drug is designated as a breakthrough therapy.",
      "Whenever contamination is found in the drug, it is not the case that there is a manufacturing issue with the drug.",
      "Either contamination is found in the drug or there is a quality control failure for the drug.",
      "Under the condition that there is a quality control failure for the drug, a recall is issued for the drug.",
      "If there is a quality control failure for the drug, then it is not the case that there is a manufacturing issue with the drug.",
      "If a recall is issued for the drug, then a manufacturing issue with the drug does not hold.",
      "Either the drug undergoes market withdrawal, or if a recall is issued for the drug, then it is not the case that there is a manufacturing issue with the drug.",
      "Provided that the company makes a financial investment in the drug, the drug is profitable.",
      "Either the company makes a financial investment in the drug or the drug receives venture capital funding.",
      "If the drug receives venture capital funding, then the drug is profitable.",
      "Provided that the company conducts an initial public offering, the company makes a financial investment in the drug.",
      "Either the company conducts an initial public offering or the drug receives private equity investment.",
      "Under the condition that the drug receives private equity investment, the drug receives venture capital funding.",
      "If an application is submitted to the regulatory agency, then if the drug is not profitable, the technology for the drug is not approved.",
      "Provided that an application is submitted to the regulatory agency, the application is reviewed by the regulatory agency.",
      "Given that the drug has a successful phase 3 trial, if the drug receives private equity investment, then the drug receives venture capital funding.",
      "Either the drug has a successful phase 3 trial or the drug receives regulatory approval.",
      "If the drug receives regulatory approval, then provided that the drug receives private equity investment, the drug receives venture capital funding.",
      "Whenever the drug receives regulatory approval, the drug is launched on the market.",
      "If the drug receives regulatory approval, then a marketing campaign is conducted for the drug.",
      "Under the condition that the drug receives regulatory approval, the drug receives reimbursement approval.",
      "Provided that the drug is launched on the market, if the drug receives private equity investment, then the drug receives venture capital funding.",
      "If a marketing campaign is conducted for the drug, then the drug is launched on the market.",
      "Given that the drug uses blockchain tracking, the drug is profitable.",
      "Either the drug uses blockchain tracking or the drug uses traditional tracking.",
      "Provided that the drug uses traditional tracking, the drug is profitable.",
      "If the drug is a counterfeit product, then the drug is an authentic product.",
      "Whenever the drug is a counterfeit product, the drug faces generic competition.",
      "Provided that the drug is a counterfeit product, it is not the case that the drug is an authentic product.",
      "Either the drug is a counterfeit product, or if the drug uses blockchain tracking, the drug is profitable.",
      "If the drug is distributed illegally, then the drug experiences a supply chain disruption.",
      "Under the condition that the drug is distributed illegally, there is a storage violation for the drug.",
      "Either the drug is distributed legally or the drug is not distributed illegally.",
      "Provided that the application is reviewed by the regulatory agency, if the drug is not profitable, then the technology for the drug is not approved.",
      "Either the drug receives full approval or it is not the case that the drug receives conditional approval.",
      "If the drug has a compliance certificate, then either the drug receives full approval or the drug does not receive conditional approval.",
      "Whenever the company undergoes an internal audit, the drug has a compliance certificate.",
      "Either the company undergoes an internal audit or the company undergoes an external audit.",
      "Provided that the company undergoes an external audit, the drug has a compliance certificate.",
      "Either the company maintains compliance or the company does not commit a regulatory violation.",
      "If the drug undergoes an accelerated review, then provided that the drug meets safety standards, if the application is reviewed by the regulatory agency, then if the drug is not profitable, the technology for the drug is not approved.",
      "Either the drug undergoes an accelerated review or the drug undergoes a standard review.",
      "Given that the drug undergoes a standard review, if the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, it is not the case that the technology for the drug is approved.",
      "Either the drug has orphan drug status, or if the drug undergoes an accelerated review, then under the condition that the drug meets safety standards, provided that the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved.",
      "Provided that clinical trials are required for the drug, if the application is reviewed by the regulatory agency, then given that the drug is not profitable, the technology for the drug is not approved.",
      "Either clinical trials are required for the drug or the drug meets safety standards.",
      "If the drug has a rare disease indication, then either the drug has orphan drug status, or provided that the drug undergoes an accelerated review, then if the drug meets safety standards, whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved.",
      "Either the drug has a rare disease indication or the drug has a common disease indication.",
      "Provided that the drug has a common disease indication, either the drug has orphan drug status, or if the drug undergoes an accelerated review, then under the condition that the drug meets safety standards, whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved.",
      "Either the drug is a combination therapy, or if the drug has a common disease indication, then either the drug has orphan drug status, or provided that the drug undergoes an accelerated review, then if the drug meets safety standards, given that the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved.",
      "If the drug has a drug interaction issue, then the drug has adverse events.",
      "Under the condition that the drug has a drug interaction issue, the drug does not have adverse events.",
      "Provided that the drug undergoes post-market surveillance, if the drug has a drug interaction issue, then it is not the case that the drug has adverse events.",
      "Whenever the drug undergoes post-market surveillance, the drug undergoes safety monitoring.",
      "Either the drug undergoes post-market surveillance or the drug undergoes pre-market testing.",
      "Given that the drug undergoes pre-market testing, if the drug has a drug interaction issue, then the drug does not have adverse events.",
      "Provided that the drug undergoes safety monitoring, if the drug has a drug interaction issue, then the drug does not have adverse events.",
      "If the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved.",
      "Either the drug has a patient assistance program or if the drug receives private equity investment, then the drug receives venture capital funding.",
      "Either the drug uses value-based pricing, or if it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, then the drug is under price control.",
      "Provided that a health economics study is conducted for the drug, either the drug uses value-based pricing, or if it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, then the drug is under price control.",
      "Either a health economics study is conducted for the drug or outcomes research is conducted for the drug.",
      "If outcomes research is conducted for the drug, then either the drug uses value-based pricing, or given that it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, the drug is under price control.",
      "Provided that a patent is filed for the drug, if it is not the case that if the drug receives regulatory approval then the drug is launched on the market, then the drug has market exclusivity.",
      "If a patent is granted for the drug, then whenever a patent is filed for the drug, if it is not the case that if the drug receives regulatory approval then the drug is launched on the market, then the drug has market exclusivity.",
      "Under the condition that a patent is granted for the drug, the drug has patent exclusivity.",
      "Provided that the drug has patent exclusivity, if a patent is filed for the drug, then given that it is not the case that if the drug receives regulatory approval then the drug is launched on the market, the drug has market exclusivity.",
      "If the drug has patent exclusivity, then the drug receives a patent extension.",
      "Whenever the drug receives a patent extension, if a patent is filed for the drug, then provided that it is not the case that if the drug receives regulatory approval then the drug is launched on the market, the drug has market exclusivity.",
      "Given that the drug has patent protection, if the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved.",
      "If the drug receives reimbursement approval, then provided that the drug receives private equity investment, the drug receives venture capital funding.",
      "Either the drug is included in a formulary or if the drug receives reimbursement approval, then if the drug receives private equity investment, the drug receives venture capital funding.",
      "Provided that the drug faces generic competition, a biosimilar version of the drug is available.",
      "Under the condition that the drug faces generic competition, it is not the case that a biosimilar version of the drug is available.",
      "If there is patent litigation for the drug, then whenever the drug faces generic competition, a biosimilar version of the drug is available.",
      "Either there is patent litigation for the drug or there is a patent settlement for the drug.",
      "Provided that there is a patent settlement for the drug, if the drug faces generic competition, then a biosimilar version of the drug is available.",
      "Whenever a manufacturing process uses technology for the drug, the drug is produced through automated production.",
      "If a manufacturing process uses technology for the drug, then the drug is produced through manual production.",
      "Provided that a manufacturing process uses technology for the drug, it is not the case that the drug is produced through automated production.",
      "Either a manufacturing process uses technology for the drug or there is no patent infringement for the drug.",
      "Under the condition that the drug is produced through manual production, the drug is produced through hybrid production.",
      "If the drug is produced through manual production, then the drug is not produced through automated production.",
      "Provided that the drug is produced through hybrid production, the drug is not produced through automated production.",
      "Given that the drug experiences a supply chain disruption, production of the drug is delayed.",
      "If the drug has an alternative supplier, then production of the drug is not delayed.",
      "Either the drug has an alternative supplier or the drug has a backup manufacturer.",
      "Whenever the drug has a backup manufacturer, production of the drug is not delayed.",
      "Provided that there is a storage violation for the drug, the drug experiences a temperature excursion.",
      "If there is a storage violation for the drug, then the drug has a humidity issue.",
      "Under the condition that the drug has a humidity issue, the drug experiences a temperature excursion.",
      "Either the drug undergoes quality assurance or if the drug has a humidity issue, then the drug experiences a temperature excursion.",
      "Either the drug undergoes batch testing or the drug does not undergo quality assurance.",
      "Either the drug undergoes a stability study, or the drug undergoes batch testing, or the drug does not undergo quality assurance.",
      "Provided that the drug receives fast track approval, if the drug is not profitable, then the clinical trial for the drug is completed.",
      "Either the drug receives fast track approval or the drug is designated as a breakthrough therapy.",
      "If it is not the case that if the drug receives regulatory approval then the drug is launched on the market, then the drug has market exclusivity.",
      "Provided that it is not the case that if the drug is a counterfeit product then the drug is an authentic product, the drug is distributed illegally.",
      "If it is not the case that if the company undergoes an internal audit then the drug has a compliance certificate, then the company commits a regulatory violation.",
      "Given that it is not the case that if the drug undergoes safety monitoring then if the drug has a drug interaction issue then the drug does not have adverse events, the drug has a risk management plan.",
      "Provided that it is not the case that if the drug meets safety standards then if the application is reviewed by the regulatory agency then if the drug is not profitable then the technology for the drug is not approved, the drug has a drug interaction issue.",
      "If it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, then the drug is under price control.",
      "Whenever it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, the drug is not under price control.",
      "Provided that it is not the case that either the drug is included in a formulary or if the drug receives reimbursement approval then if the drug receives private equity investment then the drug receives venture capital funding, the drug requires prior authorization.",
      "If it is not the case that either the drug is included in a formulary or if the drug receives reimbursement approval then if the drug receives private equity investment then the drug receives venture capital funding, then the drug does not require prior authorization.",
      "Given that it is not the case that if there is a patent settlement for the drug then if the drug faces generic competition then a biosimilar version of the drug is available, there is patent infringement for the drug.",
      "Provided that it is not the case that if it is not the case that if the drug undergoes safety monitoring then if the drug has a drug interaction issue then the drug does not have adverse events then the drug has a risk management plan, the drug has a black box warning.",
      "If it is not the case that if the drug is not profitable then the technology for the drug is not approved, then the drug receives conditional approval.",
      "Whenever the drug does not have patent protection, a generic version of the drug is available.",
      "Provided that the drug does not have patent protection, it is not the case that a generic version of the drug is available.",
      "If the drug is not profitable, then the technology for the drug is approved.",
      "Under the condition that the drug is not profitable, the clinical trial for the drug is completed.",
      "Provided that the drug is not profitable, the technology for the drug is not approved.",
      "If the drug is not profitable, then the clinical trial for the drug is not completed.",
      "An application is submitted to the regulatory agency.",
      "The drug has a compliance certificate.",
      "A patent is filed for the drug.",
      "A patent is granted for the drug.",
      "The drug has patent protection.",
      "The drug is profitable.",
      "It is not the case that there is a manufacturing issue with the drug.",
      "It is not the case that the drug undergoes market withdrawal.",
      "It is not the case that the drug is a counterfeit product.",
      "It is not the case that the drug is distributed illegally.",
      "It is not the case that the drug is distributed legally.",
      "It is not the case that the drug receives conditional approval.",
      "It is not the case that the drug receives full approval.",
      "It is not the case that the company commits a regulatory violation.",
      "It is not the case that the company maintains compliance.",
      "It is not the case that the drug has orphan drug status.",
      "It is not the case that the drug is a combination therapy.",
      "It is not the case that the drug has a drug interaction issue.",
      "It is not the case that the drug has a risk management plan.",
      "It is not the case that the drug has a black box warning.",
      "It is not the case that the drug has a patient assistance program.",
      "It is not the case that the drug uses value-based pricing.",
      "It is not the case that the drug has market exclusivity.",
      "It is not the case that the drug is included in a formulary.",
      "It is not the case that the drug faces generic competition.",
      "It is not the case that there is patent infringement for the drug.",
      "It is not the case that a manufacturing process uses technology for the drug.",
      "It is not the case that the drug experiences a supply chain disruption.",
      "It is not the case that production of the drug is delayed.",
      "It is not the case that there is a storage violation for the drug.",
      "It is not the case that the drug experiences a temperature excursion.",
      "It is not the case that the drug undergoes quality assurance.",
      "It is not the case that the drug undergoes batch testing.",
      "It is not the case that the drug undergoes a stability study."
    ],
    "node_mappings": {
      "(A10 → (¬G → A8))": {
        "formal": "(A10 → (¬G → A8))",
        "prover9": "(A10 -> (-G -> A8))",
        "prover9_expression": "(breakthrough_therapy(drug) -> (-profitable(drug) -> clinical_trial_completed(drug)))",
        "natural": "Provided that the drug is designated as a breakthrough therapy, if the drug is not profitable, then the clinical trial for the drug is completed."
      },
      "(A11 ∨ (A9 ∨ A10))": {
        "formal": "(A11 ∨ (A9 ∨ A10))",
        "prover9": "(A11 | (A9 | A10))",
        "prover9_expression": "(manufacturing_issue(drug) | (fast_track_approval(drug) | breakthrough_therapy(drug)))",
        "natural": "Either there is a manufacturing issue with the drug, or the drug receives fast track approval, or the drug is designated as a breakthrough therapy."
      },
      "(A12 → ¬A11)": {
        "formal": "(A12 → ¬A11)",
        "prover9": "(A12 -> -A11)",
        "prover9_expression": "(contamination_found(drug) -> -manufacturing_issue(drug))",
        "natural": "Whenever contamination is found in the drug, it is not the case that there is a manufacturing issue with the drug."
      },
      "(A12 ∨ A13)": {
        "formal": "(A12 ∨ A13)",
        "prover9": "(A12 | A13)",
        "prover9_expression": "(contamination_found(drug) | quality_control_failure(drug))",
        "natural": "Either contamination is found in the drug or there is a quality control failure for the drug."
      },
      "(A13 → A14)": {
        "formal": "(A13 → A14)",
        "prover9": "(A13 -> A14)",
        "prover9_expression": "(quality_control_failure(drug) -> recall_issued(drug))",
        "natural": "Under the condition that there is a quality control failure for the drug, a recall is issued for the drug."
      },
      "(A13 → ¬A11)": {
        "formal": "(A13 → ¬A11)",
        "prover9": "(A13 -> -A11)",
        "prover9_expression": "(quality_control_failure(drug) -> -manufacturing_issue(drug))",
        "natural": "If there is a quality control failure for the drug, then it is not the case that there is a manufacturing issue with the drug."
      },
      "(A14 → ¬A11)": {
        "formal": "(A14 → ¬A11)",
        "prover9": "(A14 -> -A11)",
        "prover9_expression": "(recall_issued(drug) -> -manufacturing_issue(drug))",
        "natural": "If a recall is issued for the drug, then a manufacturing issue with the drug does not hold."
      },
      "(A15 ∨ (A14 → ¬A11))": {
        "formal": "(A15 ∨ (A14 → ¬A11))",
        "prover9": "(A15 | (A14 -> -A11))",
        "prover9_expression": "(market_withdrawal(drug) | (recall_issued(drug) -> -manufacturing_issue(drug)))",
        "natural": "Either the drug undergoes market withdrawal, or if a recall is issued for the drug, then it is not the case that there is a manufacturing issue with the drug."
      },
      "(A16 → G)": {
        "formal": "(A16 → G)",
        "prover9": "(A16 -> G)",
        "prover9_expression": "(financial_investment(company,drug) -> profitable(drug))",
        "natural": "Provided that the company makes a financial investment in the drug, the drug is profitable."
      },
      "(A16 ∨ A17)": {
        "formal": "(A16 ∨ A17)",
        "prover9": "(A16 | A17)",
        "prover9_expression": "(financial_investment(company,drug) | venture_capital_funding(drug))",
        "natural": "Either the company makes a financial investment in the drug or the drug receives venture capital funding."
      },
      "(A17 → G)": {
        "formal": "(A17 → G)",
        "prover9": "(A17 -> G)",
        "prover9_expression": "(venture_capital_funding(drug) -> profitable(drug))",
        "natural": "If the drug receives venture capital funding, then the drug is profitable."
      },
      "(A18 → A16)": {
        "formal": "(A18 → A16)",
        "prover9": "(A18 -> A16)",
        "prover9_expression": "(initial_public_offering(company) -> financial_investment(company,drug))",
        "natural": "Provided that the company conducts an initial public offering, the company makes a financial investment in the drug."
      },
      "(A18 ∨ A19)": {
        "formal": "(A18 ∨ A19)",
        "prover9": "(A18 | A19)",
        "prover9_expression": "(initial_public_offering(company) | private_equity_investment(drug))",
        "natural": "Either the company conducts an initial public offering or the drug receives private equity investment."
      },
      "(A19 → A17)": {
        "formal": "(A19 → A17)",
        "prover9": "(A19 -> A17)",
        "prover9_expression": "(private_equity_investment(drug) -> venture_capital_funding(drug))",
        "natural": "Under the condition that the drug receives private equity investment, the drug receives venture capital funding."
      },
      "(A2 → (¬G → ¬A1))": {
        "formal": "(A2 → (¬G → ¬A1))",
        "prover9": "(A2 -> (-G -> -A1))",
        "prover9_expression": "(submitted(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))",
        "natural": "If an application is submitted to the regulatory agency, then if the drug is not profitable, the technology for the drug is not approved."
      },
      "(A2 → A3)": {
        "formal": "(A2 → A3)",
        "prover9": "(A2 -> A3)",
        "prover9_expression": "(submitted(application,regulatory_agency) -> reviewed(application,regulatory_agency))",
        "natural": "Provided that an application is submitted to the regulatory agency, the application is reviewed by the regulatory agency."
      },
      "(A20 → (A19 → A17))": {
        "formal": "(A20 → (A19 → A17))",
        "prover9": "(A20 -> (A19 -> A17))",
        "prover9_expression": "(successful_phase3_trial(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))",
        "natural": "Given that the drug has a successful phase 3 trial, if the drug receives private equity investment, then the drug receives venture capital funding."
      },
      "(A20 ∨ A21)": {
        "formal": "(A20 ∨ A21)",
        "prover9": "(A20 | A21)",
        "prover9_expression": "(successful_phase3_trial(drug) | regulatory_approval(drug))",
        "natural": "Either the drug has a successful phase 3 trial or the drug receives regulatory approval."
      },
      "(A21 → (A19 → A17))": {
        "formal": "(A21 → (A19 → A17))",
        "prover9": "(A21 -> (A19 -> A17))",
        "prover9_expression": "(regulatory_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))",
        "natural": "If the drug receives regulatory approval, then provided that the drug receives private equity investment, the drug receives venture capital funding."
      },
      "(A21 → A22)": {
        "formal": "(A21 → A22)",
        "prover9": "(A21 -> A22)",
        "prover9_expression": "(regulatory_approval(drug) -> market_launch(drug))",
        "natural": "Whenever the drug receives regulatory approval, the drug is launched on the market."
      },
      "(A21 → A23)": {
        "formal": "(A21 → A23)",
        "prover9": "(A21 -> A23)",
        "prover9_expression": "(regulatory_approval(drug) -> marketing_campaign(drug))",
        "natural": "If the drug receives regulatory approval, then a marketing campaign is conducted for the drug."
      },
      "(A21 → A60)": {
        "formal": "(A21 → A60)",
        "prover9": "(A21 -> A60)",
        "prover9_expression": "(regulatory_approval(drug) -> reimbursement_approval(drug))",
        "natural": "Under the condition that the drug receives regulatory approval, the drug receives reimbursement approval."
      },
      "(A22 → (A19 → A17))": {
        "formal": "(A22 → (A19 → A17))",
        "prover9": "(A22 -> (A19 -> A17))",
        "prover9_expression": "(market_launch(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))",
        "natural": "Provided that the drug is launched on the market, if the drug receives private equity investment, then the drug receives venture capital funding."
      },
      "(A23 → A22)": {
        "formal": "(A23 → A22)",
        "prover9": "(A23 -> A22)",
        "prover9_expression": "(marketing_campaign(drug) -> market_launch(drug))",
        "natural": "If a marketing campaign is conducted for the drug, then the drug is launched on the market."
      },
      "(A24 → G)": {
        "formal": "(A24 → G)",
        "prover9": "(A24 -> G)",
        "prover9_expression": "(blockchain_tracking(drug) -> profitable(drug))",
        "natural": "Given that the drug uses blockchain tracking, the drug is profitable."
      },
      "(A24 ∨ A25)": {
        "formal": "(A24 ∨ A25)",
        "prover9": "(A24 | A25)",
        "prover9_expression": "(blockchain_tracking(drug) | traditional_tracking(drug))",
        "natural": "Either the drug uses blockchain tracking or the drug uses traditional tracking."
      },
      "(A25 → G)": {
        "formal": "(A25 → G)",
        "prover9": "(A25 -> G)",
        "prover9_expression": "(traditional_tracking(drug) -> profitable(drug))",
        "natural": "Provided that the drug uses traditional tracking, the drug is profitable."
      },
      "(A26 → A27)": {
        "formal": "(A26 → A27)",
        "prover9": "(A26 -> A27)",
        "prover9_expression": "(counterfeit_product(drug) -> authentic_product(drug))",
        "natural": "If the drug is a counterfeit product, then the drug is an authentic product."
      },
      "(A26 → A63)": {
        "formal": "(A26 → A63)",
        "prover9": "(A26 -> A63)",
        "prover9_expression": "(counterfeit_product(drug) -> generic_competition(drug))",
        "natural": "Whenever the drug is a counterfeit product, the drug faces generic competition."
      },
      "(A26 → ¬A27)": {
        "formal": "(A26 → ¬A27)",
        "prover9": "(A26 -> -A27)",
        "prover9_expression": "(counterfeit_product(drug) -> -authentic_product(drug))",
        "natural": "Provided that the drug is a counterfeit product, it is not the case that the drug is an authentic product."
      },
      "(A26 ∨ (A24 → G))": {
        "formal": "(A26 ∨ (A24 → G))",
        "prover9": "(A26 | (A24 -> G))",
        "prover9_expression": "(counterfeit_product(drug) | (blockchain_tracking(drug) -> profitable(drug)))",
        "natural": "Either the drug is a counterfeit product, or if the drug uses blockchain tracking, the drug is profitable."
      },
      "(A28 → A72)": {
        "formal": "(A28 → A72)",
        "prover9": "(A28 -> A72)",
        "prover9_expression": "(illegal_distribution(drug) -> supply_chain_disruption(drug))",
        "natural": "If the drug is distributed illegally, then the drug experiences a supply chain disruption."
      },
      "(A28 → A76)": {
        "formal": "(A28 → A76)",
        "prover9": "(A28 -> A76)",
        "prover9_expression": "(illegal_distribution(drug) -> storage_violation(drug))",
        "natural": "Under the condition that the drug is distributed illegally, there is a storage violation for the drug."
      },
      "(A29 ∨ ¬A28)": {
        "formal": "(A29 ∨ ¬A28)",
        "prover9": "(A29 | -A28)",
        "prover9_expression": "(legal_distribution(drug) | -illegal_distribution(drug))",
        "natural": "Either the drug is distributed legally or the drug is not distributed illegally."
      },
      "(A3 → (¬G → ¬A1))": {
        "formal": "(A3 → (¬G → ¬A1))",
        "prover9": "(A3 -> (-G -> -A1))",
        "prover9_expression": "(reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))",
        "natural": "Provided that the application is reviewed by the regulatory agency, if the drug is not profitable, then the technology for the drug is not approved."
      },
      "(A31 ∨ ¬A30)": {
        "formal": "(A31 ∨ ¬A30)",
        "prover9": "(A31 | -A30)",
        "prover9_expression": "(full_approval(drug) | -conditional_approval(drug))",
        "natural": "Either the drug receives full approval or it is not the case that the drug receives conditional approval."
      },
      "(A32 → (A31 ∨ ¬A30))": {
        "formal": "(A32 → (A31 ∨ ¬A30))",
        "prover9": "(A32 -> (A31 | -A30))",
        "prover9_expression": "(compliance_certificate(drug) -> (full_approval(drug) | -conditional_approval(drug)))",
        "natural": "If the drug has a compliance certificate, then either the drug receives full approval or the drug does not receive conditional approval."
      },
      "(A33 → A32)": {
        "formal": "(A33 → A32)",
        "prover9": "(A33 -> A32)",
        "prover9_expression": "(internal_audit(company) -> compliance_certificate(drug))",
        "natural": "Whenever the company undergoes an internal audit, the drug has a compliance certificate."
      },
      "(A33 ∨ A34)": {
        "formal": "(A33 ∨ A34)",
        "prover9": "(A33 | A34)",
        "prover9_expression": "(internal_audit(company) | external_audit(company))",
        "natural": "Either the company undergoes an internal audit or the company undergoes an external audit."
      },
      "(A34 → A32)": {
        "formal": "(A34 → A32)",
        "prover9": "(A34 -> A32)",
        "prover9_expression": "(external_audit(company) -> compliance_certificate(drug))",
        "natural": "Provided that the company undergoes an external audit, the drug has a compliance certificate."
      },
      "(A36 ∨ ¬A35)": {
        "formal": "(A36 ∨ ¬A35)",
        "prover9": "(A36 | -A35)",
        "prover9_expression": "(compliance_maintained(company) | -regulatory_violation(company))",
        "natural": "Either the company maintains compliance or the company does not commit a regulatory violation."
      },
      "(A37 → (A5 → (A3 → (¬G → ¬A1))))": {
        "formal": "(A37 → (A5 → (A3 → (¬G → ¬A1))))",
        "prover9": "(A37 -> (A5 -> (A3 -> (-G -> -A1))))",
        "prover9_expression": "(accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))",
        "natural": "If the drug undergoes an accelerated review, then provided that the drug meets safety standards, if the application is reviewed by the regulatory agency, then if the drug is not profitable, the technology for the drug is not approved."
      },
      "(A37 ∨ A38)": {
        "formal": "(A37 ∨ A38)",
        "prover9": "(A37 | A38)",
        "prover9_expression": "(accelerated_review(drug) | standard_review(drug))",
        "natural": "Either the drug undergoes an accelerated review or the drug undergoes a standard review."
      },
      "(A38 → (A5 → (A3 → (¬G → ¬A1))))": {
        "formal": "(A38 → (A5 → (A3 → (¬G → ¬A1))))",
        "prover9": "(A38 -> (A5 -> (A3 -> (-G -> -A1))))",
        "prover9_expression": "(standard_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))",
        "natural": "Given that the drug undergoes a standard review, if the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, it is not the case that the technology for the drug is approved."
      },
      "(A39 ∨ (A37 → (A5 → (A3 → (¬G → ¬A1)))))": {
        "formal": "(A39 ∨ (A37 → (A5 → (A3 → (¬G → ¬A1)))))",
        "prover9": "(A39 | (A37 -> (A5 -> (A3 -> (-G -> -A1)))))",
        "prover9_expression": "(orphan_drug_status(drug) | (accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug))))))",
        "natural": "Either the drug has orphan drug status, or if the drug undergoes an accelerated review, then under the condition that the drug meets safety standards, provided that the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
      },
      "(A4 → (A3 → (¬G → ¬A1)))": {
        "formal": "(A4 → (A3 → (¬G → ¬A1)))",
        "prover9": "(A4 -> (A3 -> (-G -> -A1)))",
        "prover9_expression": "(requires_clinical_trials(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug))))",
        "natural": "Provided that clinical trials are required for the drug, if the application is reviewed by the regulatory agency, then given that the drug is not profitable, the technology for the drug is not approved."
      },
      "(A4 ∨ A5)": {
        "formal": "(A4 ∨ A5)",
        "prover9": "(A4 | A5)",
        "prover9_expression": "(requires_clinical_trials(drug) | meets_safety_standards(drug))",
        "natural": "Either clinical trials are required for the drug or the drug meets safety standards."
      },
      "(A40 → (A39 ∨ (A37 → (A5 → (A3 → (¬G → ¬A1))))))": {
        "formal": "(A40 → (A39 ∨ (A37 → (A5 → (A3 → (¬G → ¬A1))))))",
        "prover9": "(A40 -> (A39 | (A37 -> (A5 -> (A3 -> (-G -> -A1))))))",
        "prover9_expression": "(rare_disease_indication(drug) -> (orphan_drug_status(drug) | (accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))))",
        "natural": "If the drug has a rare disease indication, then either the drug has orphan drug status, or provided that the drug undergoes an accelerated review, then if the drug meets safety standards, whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
      },
      "(A40 ∨ A41)": {
        "formal": "(A40 ∨ A41)",
        "prover9": "(A40 | A41)",
        "prover9_expression": "(rare_disease_indication(drug) | common_disease_indication(drug))",
        "natural": "Either the drug has a rare disease indication or the drug has a common disease indication."
      },
      "(A41 → (A39 ∨ (A37 → (A5 → (A3 → (¬G → ¬A1))))))": {
        "formal": "(A41 → (A39 ∨ (A37 → (A5 → (A3 → (¬G → ¬A1))))))",
        "prover9": "(A41 -> (A39 | (A37 -> (A5 -> (A3 -> (-G -> -A1))))))",
        "prover9_expression": "(common_disease_indication(drug) -> (orphan_drug_status(drug) | (accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))))",
        "natural": "Provided that the drug has a common disease indication, either the drug has orphan drug status, or if the drug undergoes an accelerated review, then under the condition that the drug meets safety standards, whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
      },
      "(A42 ∨ (A41 → (A39 ∨ (A37 → (A5 → (A3 → (¬G → ¬A1)))))))": {
        "formal": "(A42 ∨ (A41 → (A39 ∨ (A37 → (A5 → (A3 → (¬G → ¬A1)))))))",
        "prover9": "(A42 | (A41 -> (A39 | (A37 -> (A5 -> (A3 -> (-G -> -A1)))))))",
        "prover9_expression": "(combination_therapy(drug) | (common_disease_indication(drug) -> (orphan_drug_status(drug) | (accelerated_review(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug))))))))",
        "natural": "Either the drug is a combination therapy, or if the drug has a common disease indication, then either the drug has orphan drug status, or provided that the drug undergoes an accelerated review, then if the drug meets safety standards, given that the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
      },
      "(A43 → A44)": {
        "formal": "(A43 → A44)",
        "prover9": "(A43 -> A44)",
        "prover9_expression": "(drug_interaction_issue(drug) -> adverse_events(drug))",
        "natural": "If the drug has a drug interaction issue, then the drug has adverse events."
      },
      "(A43 → ¬A44)": {
        "formal": "(A43 → ¬A44)",
        "prover9": "(A43 -> -A44)",
        "prover9_expression": "(drug_interaction_issue(drug) -> -adverse_events(drug))",
        "natural": "Under the condition that the drug has a drug interaction issue, the drug does not have adverse events."
      },
      "(A45 → (A43 → ¬A44))": {
        "formal": "(A45 → (A43 → ¬A44))",
        "prover9": "(A45 -> (A43 -> -A44))",
        "prover9_expression": "(post_market_surveillance(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug)))",
        "natural": "Provided that the drug undergoes post-market surveillance, if the drug has a drug interaction issue, then it is not the case that the drug has adverse events."
      },
      "(A45 → A47)": {
        "formal": "(A45 → A47)",
        "prover9": "(A45 -> A47)",
        "prover9_expression": "(post_market_surveillance(drug) -> safety_monitoring(drug))",
        "natural": "Whenever the drug undergoes post-market surveillance, the drug undergoes safety monitoring."
      },
      "(A45 ∨ A46)": {
        "formal": "(A45 ∨ A46)",
        "prover9": "(A45 | A46)",
        "prover9_expression": "(post_market_surveillance(drug) | pre_market_testing(drug))",
        "natural": "Either the drug undergoes post-market surveillance or the drug undergoes pre-market testing."
      },
      "(A46 → (A43 → ¬A44))": {
        "formal": "(A46 → (A43 → ¬A44))",
        "prover9": "(A46 -> (A43 -> -A44))",
        "prover9_expression": "(pre_market_testing(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug)))",
        "natural": "Given that the drug undergoes pre-market testing, if the drug has a drug interaction issue, then the drug does not have adverse events."
      },
      "(A47 → (A43 → ¬A44))": {
        "formal": "(A47 → (A43 → ¬A44))",
        "prover9": "(A47 -> (A43 -> -A44))",
        "prover9_expression": "(safety_monitoring(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug)))",
        "natural": "Provided that the drug undergoes safety monitoring, if the drug has a drug interaction issue, then the drug does not have adverse events."
      },
      "(A5 → (A3 → (¬G → ¬A1)))": {
        "formal": "(A5 → (A3 → (¬G → ¬A1)))",
        "prover9": "(A5 -> (A3 -> (-G -> -A1)))",
        "prover9_expression": "(meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug))))",
        "natural": "If the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
      },
      "(A50 ∨ (A19 → A17))": {
        "formal": "(A50 ∨ (A19 → A17))",
        "prover9": "(A50 | (A19 -> A17))",
        "prover9_expression": "(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug)))",
        "natural": "Either the drug has a patient assistance program or if the drug receives private equity investment, then the drug receives venture capital funding."
      },
      "(A52 ∨ (¬(A50 ∨ (A19 → A17)) → A51))": {
        "formal": "(A52 ∨ (¬(A50 ∨ (A19 → A17)) → A51))",
        "prover9": "(A52 | (-(A50 | (A19 -> A17)) -> A51))",
        "prover9_expression": "(value_based_pricing(drug) | (-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> price_control(drug)))",
        "natural": "Either the drug uses value-based pricing, or if it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, then the drug is under price control."
      },
      "(A53 → (A52 ∨ (¬(A50 ∨ (A19 → A17)) → A51)))": {
        "formal": "(A53 → (A52 ∨ (¬(A50 ∨ (A19 → A17)) → A51)))",
        "prover9": "(A53 -> (A52 | (-(A50 | (A19 -> A17)) -> A51)))",
        "prover9_expression": "(health_economics_study(drug) -> (value_based_pricing(drug) | (-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> price_control(drug))))",
        "natural": "Provided that a health economics study is conducted for the drug, either the drug uses value-based pricing, or if it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, then the drug is under price control."
      },
      "(A53 ∨ A54)": {
        "formal": "(A53 ∨ A54)",
        "prover9": "(A53 | A54)",
        "prover9_expression": "(health_economics_study(drug) | outcomes_research(drug))",
        "natural": "Either a health economics study is conducted for the drug or outcomes research is conducted for the drug."
      },
      "(A54 → (A52 ∨ (¬(A50 ∨ (A19 → A17)) → A51)))": {
        "formal": "(A54 → (A52 ∨ (¬(A50 ∨ (A19 → A17)) → A51)))",
        "prover9": "(A54 -> (A52 | (-(A50 | (A19 -> A17)) -> A51)))",
        "prover9_expression": "(outcomes_research(drug) -> (value_based_pricing(drug) | (-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> price_control(drug))))",
        "natural": "If outcomes research is conducted for the drug, then either the drug uses value-based pricing, or given that it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, the drug is under price control."
      },
      "(A56 → (¬(A21 → A22) → A55))": {
        "formal": "(A56 → (¬(A21 → A22) → A55))",
        "prover9": "(A56 -> (-(A21 -> A22) -> A55))",
        "prover9_expression": "(patent_filing(drug) -> (-(regulatory_approval(drug) -> market_launch(drug)) -> market_exclusivity(drug)))",
        "natural": "Provided that a patent is filed for the drug, if it is not the case that if the drug receives regulatory approval then the drug is launched on the market, then the drug has market exclusivity."
      },
      "(A57 → (A56 → (¬(A21 → A22) → A55)))": {
        "formal": "(A57 → (A56 → (¬(A21 → A22) → A55)))",
        "prover9": "(A57 -> (A56 -> (-(A21 -> A22) -> A55)))",
        "prover9_expression": "(patent_granted(drug) -> (patent_filing(drug) -> (-(regulatory_approval(drug) -> market_launch(drug)) -> market_exclusivity(drug))))",
        "natural": "If a patent is granted for the drug, then whenever a patent is filed for the drug, if it is not the case that if the drug receives regulatory approval then the drug is launched on the market, then the drug has market exclusivity."
      },
      "(A57 → A58)": {
        "formal": "(A57 → A58)",
        "prover9": "(A57 -> A58)",
        "prover9_expression": "(patent_granted(drug) -> patent_exclusivity(drug))",
        "natural": "Under the condition that a patent is granted for the drug, the drug has patent exclusivity."
      },
      "(A58 → (A56 → (¬(A21 → A22) → A55)))": {
        "formal": "(A58 → (A56 → (¬(A21 → A22) → A55)))",
        "prover9": "(A58 -> (A56 -> (-(A21 -> A22) -> A55)))",
        "prover9_expression": "(patent_exclusivity(drug) -> (patent_filing(drug) -> (-(regulatory_approval(drug) -> market_launch(drug)) -> market_exclusivity(drug))))",
        "natural": "Provided that the drug has patent exclusivity, if a patent is filed for the drug, then given that it is not the case that if the drug receives regulatory approval then the drug is launched on the market, the drug has market exclusivity."
      },
      "(A58 → A59)": {
        "formal": "(A58 → A59)",
        "prover9": "(A58 -> A59)",
        "prover9_expression": "(patent_exclusivity(drug) -> patent_extension(drug))",
        "natural": "If the drug has patent exclusivity, then the drug receives a patent extension."
      },
      "(A59 → (A56 → (¬(A21 → A22) → A55)))": {
        "formal": "(A59 → (A56 → (¬(A21 → A22) → A55)))",
        "prover9": "(A59 -> (A56 -> (-(A21 -> A22) -> A55)))",
        "prover9_expression": "(patent_extension(drug) -> (patent_filing(drug) -> (-(regulatory_approval(drug) -> market_launch(drug)) -> market_exclusivity(drug))))",
        "natural": "Whenever the drug receives a patent extension, if a patent is filed for the drug, then provided that it is not the case that if the drug receives regulatory approval then the drug is launched on the market, the drug has market exclusivity."
      },
      "(A6 → (A5 → (A3 → (¬G → ¬A1))))": {
        "formal": "(A6 → (A5 → (A3 → (¬G → ¬A1))))",
        "prover9": "(A6 -> (A5 -> (A3 -> (-G -> -A1))))",
        "prover9_expression": "(has_patent_protection(drug) -> (meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))))",
        "natural": "Given that the drug has patent protection, if the drug meets safety standards, then whenever the application is reviewed by the regulatory agency, if the drug is not profitable, the technology for the drug is not approved."
      },
      "(A60 → (A19 → A17))": {
        "formal": "(A60 → (A19 → A17))",
        "prover9": "(A60 -> (A19 -> A17))",
        "prover9_expression": "(reimbursement_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))",
        "natural": "If the drug receives reimbursement approval, then provided that the drug receives private equity investment, the drug receives venture capital funding."
      },
      "(A61 ∨ (A60 → (A19 → A17)))": {
        "formal": "(A61 ∨ (A60 → (A19 → A17)))",
        "prover9": "(A61 | (A60 -> (A19 -> A17)))",
        "prover9_expression": "(formulary_inclusion(drug) | (reimbursement_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug))))",
        "natural": "Either the drug is included in a formulary or if the drug receives reimbursement approval, then if the drug receives private equity investment, the drug receives venture capital funding."
      },
      "(A63 → A64)": {
        "formal": "(A63 → A64)",
        "prover9": "(A63 -> A64)",
        "prover9_expression": "(generic_competition(drug) -> biosimilar_version(drug))",
        "natural": "Provided that the drug faces generic competition, a biosimilar version of the drug is available."
      },
      "(A63 → ¬A64)": {
        "formal": "(A63 → ¬A64)",
        "prover9": "(A63 -> -A64)",
        "prover9_expression": "(generic_competition(drug) -> -biosimilar_version(drug))",
        "natural": "Under the condition that the drug faces generic competition, it is not the case that a biosimilar version of the drug is available."
      },
      "(A65 → (A63 → A64))": {
        "formal": "(A65 → (A63 → A64))",
        "prover9": "(A65 -> (A63 -> A64))",
        "prover9_expression": "(patent_litigation(drug) -> (generic_competition(drug) -> biosimilar_version(drug)))",
        "natural": "If there is patent litigation for the drug, then whenever the drug faces generic competition, a biosimilar version of the drug is available."
      },
      "(A65 ∨ A66)": {
        "formal": "(A65 ∨ A66)",
        "prover9": "(A65 | A66)",
        "prover9_expression": "(patent_litigation(drug) | patent_settlement(drug))",
        "natural": "Either there is patent litigation for the drug or there is a patent settlement for the drug."
      },
      "(A66 → (A63 → A64))": {
        "formal": "(A66 → (A63 → A64))",
        "prover9": "(A66 -> (A63 -> A64))",
        "prover9_expression": "(patent_settlement(drug) -> (generic_competition(drug) -> biosimilar_version(drug)))",
        "natural": "Provided that there is a patent settlement for the drug, if the drug faces generic competition, then a biosimilar version of the drug is available."
      },
      "(A68 → A69)": {
        "formal": "(A68 → A69)",
        "prover9": "(A68 -> A69)",
        "prover9_expression": "(manufacturing_process(technology,drug) -> automated_production(drug))",
        "natural": "Whenever a manufacturing process uses technology for the drug, the drug is produced through automated production."
      },
      "(A68 → A70)": {
        "formal": "(A68 → A70)",
        "prover9": "(A68 -> A70)",
        "prover9_expression": "(manufacturing_process(technology,drug) -> manual_production(drug))",
        "natural": "If a manufacturing process uses technology for the drug, then the drug is produced through manual production."
      },
      "(A68 → ¬A69)": {
        "formal": "(A68 → ¬A69)",
        "prover9": "(A68 -> -A69)",
        "prover9_expression": "(manufacturing_process(technology,drug) -> -automated_production(drug))",
        "natural": "Provided that a manufacturing process uses technology for the drug, it is not the case that the drug is produced through automated production."
      },
      "(A68 ∨ ¬A67)": {
        "formal": "(A68 ∨ ¬A67)",
        "prover9": "(A68 | -A67)",
        "prover9_expression": "(manufacturing_process(technology,drug) | -patent_infringement(drug))",
        "natural": "Either a manufacturing process uses technology for the drug or there is no patent infringement for the drug."
      },
      "(A70 → A71)": {
        "formal": "(A70 → A71)",
        "prover9": "(A70 -> A71)",
        "prover9_expression": "(manual_production(drug) -> hybrid_production(drug))",
        "natural": "Under the condition that the drug is produced through manual production, the drug is produced through hybrid production."
      },
      "(A70 → ¬A69)": {
        "formal": "(A70 → ¬A69)",
        "prover9": "(A70 -> -A69)",
        "prover9_expression": "(manual_production(drug) -> -automated_production(drug))",
        "natural": "If the drug is produced through manual production, then the drug is not produced through automated production."
      },
      "(A71 → ¬A69)": {
        "formal": "(A71 → ¬A69)",
        "prover9": "(A71 -> -A69)",
        "prover9_expression": "(hybrid_production(drug) -> -automated_production(drug))",
        "natural": "Provided that the drug is produced through hybrid production, the drug is not produced through automated production."
      },
      "(A72 → A73)": {
        "formal": "(A72 → A73)",
        "prover9": "(A72 -> A73)",
        "prover9_expression": "(supply_chain_disruption(drug) -> production_delayed(drug))",
        "natural": "Given that the drug experiences a supply chain disruption, production of the drug is delayed."
      },
      "(A74 → ¬A73)": {
        "formal": "(A74 → ¬A73)",
        "prover9": "(A74 -> -A73)",
        "prover9_expression": "(alternative_supplier(drug) -> -production_delayed(drug))",
        "natural": "If the drug has an alternative supplier, then production of the drug is not delayed."
      },
      "(A74 ∨ A75)": {
        "formal": "(A74 ∨ A75)",
        "prover9": "(A74 | A75)",
        "prover9_expression": "(alternative_supplier(drug) | backup_manufacturer(drug))",
        "natural": "Either the drug has an alternative supplier or the drug has a backup manufacturer."
      },
      "(A75 → ¬A73)": {
        "formal": "(A75 → ¬A73)",
        "prover9": "(A75 -> -A73)",
        "prover9_expression": "(backup_manufacturer(drug) -> -production_delayed(drug))",
        "natural": "Whenever the drug has a backup manufacturer, production of the drug is not delayed."
      },
      "(A76 → A77)": {
        "formal": "(A76 → A77)",
        "prover9": "(A76 -> A77)",
        "prover9_expression": "(storage_violation(drug) -> temperature_excursion(drug))",
        "natural": "Provided that there is a storage violation for the drug, the drug experiences a temperature excursion."
      },
      "(A76 → A78)": {
        "formal": "(A76 → A78)",
        "prover9": "(A76 -> A78)",
        "prover9_expression": "(storage_violation(drug) -> humidity_issue(drug))",
        "natural": "If there is a storage violation for the drug, then the drug has a humidity issue."
      },
      "(A78 → A77)": {
        "formal": "(A78 → A77)",
        "prover9": "(A78 -> A77)",
        "prover9_expression": "(humidity_issue(drug) -> temperature_excursion(drug))",
        "natural": "Under the condition that the drug has a humidity issue, the drug experiences a temperature excursion."
      },
      "(A79 ∨ (A78 → A77))": {
        "formal": "(A79 ∨ (A78 → A77))",
        "prover9": "(A79 | (A78 -> A77))",
        "prover9_expression": "(quality_assurance(drug) | (humidity_issue(drug) -> temperature_excursion(drug)))",
        "natural": "Either the drug undergoes quality assurance or if the drug has a humidity issue, then the drug experiences a temperature excursion."
      },
      "(A80 ∨ ¬A79)": {
        "formal": "(A80 ∨ ¬A79)",
        "prover9": "(A80 | -A79)",
        "prover9_expression": "(batch_testing(drug) | -quality_assurance(drug))",
        "natural": "Either the drug undergoes batch testing or the drug does not undergo quality assurance."
      },
      "(A81 ∨ (A80 ∨ ¬A79))": {
        "formal": "(A81 ∨ (A80 ∨ ¬A79))",
        "prover9": "(A81 | (A80 | -A79))",
        "prover9_expression": "(stability_study(drug) | (batch_testing(drug) | -quality_assurance(drug)))",
        "natural": "Either the drug undergoes a stability study, or the drug undergoes batch testing, or the drug does not undergo quality assurance."
      },
      "(A9 → (¬G → A8))": {
        "formal": "(A9 → (¬G → A8))",
        "prover9": "(A9 -> (-G -> A8))",
        "prover9_expression": "(fast_track_approval(drug) -> (-profitable(drug) -> clinical_trial_completed(drug)))",
        "natural": "Provided that the drug receives fast track approval, if the drug is not profitable, then the clinical trial for the drug is completed."
      },
      "(A9 ∨ A10)": {
        "formal": "(A9 ∨ A10)",
        "prover9": "(A9 | A10)",
        "prover9_expression": "(fast_track_approval(drug) | breakthrough_therapy(drug))",
        "natural": "Either the drug receives fast track approval or the drug is designated as a breakthrough therapy."
      },
      "(¬(A21 → A22) → A55)": {
        "formal": "(¬(A21 → A22) → A55)",
        "prover9": "(-(A21 -> A22) -> A55)",
        "prover9_expression": "(-(regulatory_approval(drug) -> market_launch(drug)) -> market_exclusivity(drug))",
        "natural": "If it is not the case that if the drug receives regulatory approval then the drug is launched on the market, then the drug has market exclusivity."
      },
      "(¬(A26 → A27) → A28)": {
        "formal": "(¬(A26 → A27) → A28)",
        "prover9": "(-(A26 -> A27) -> A28)",
        "prover9_expression": "(-(counterfeit_product(drug) -> authentic_product(drug)) -> illegal_distribution(drug))",
        "natural": "Provided that it is not the case that if the drug is a counterfeit product then the drug is an authentic product, the drug is distributed illegally."
      },
      "(¬(A33 → A32) → A35)": {
        "formal": "(¬(A33 → A32) → A35)",
        "prover9": "(-(A33 -> A32) -> A35)",
        "prover9_expression": "(-(internal_audit(company) -> compliance_certificate(drug)) -> regulatory_violation(company))",
        "natural": "If it is not the case that if the company undergoes an internal audit then the drug has a compliance certificate, then the company commits a regulatory violation."
      },
      "(¬(A47 → (A43 → ¬A44)) → A48)": {
        "formal": "(¬(A47 → (A43 → ¬A44)) → A48)",
        "prover9": "(-(A47 -> (A43 -> -A44)) -> A48)",
        "prover9_expression": "(-(safety_monitoring(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug))) -> risk_management_plan(drug))",
        "natural": "Given that it is not the case that if the drug undergoes safety monitoring then if the drug has a drug interaction issue then the drug does not have adverse events, the drug has a risk management plan."
      },
      "(¬(A5 → (A3 → (¬G → ¬A1))) → A43)": {
        "formal": "(¬(A5 → (A3 → (¬G → ¬A1))) → A43)",
        "prover9": "(-(A5 -> (A3 -> (-G -> -A1))) -> A43)",
        "prover9_expression": "(-(meets_safety_standards(drug) -> (reviewed(application,regulatory_agency) -> (-profitable(drug) -> -approved(technology,drug)))) -> drug_interaction_issue(drug))",
        "natural": "Provided that it is not the case that if the drug meets safety standards then if the application is reviewed by the regulatory agency then if the drug is not profitable then the technology for the drug is not approved, the drug has a drug interaction issue."
      },
      "(¬(A50 ∨ (A19 → A17)) → A51)": {
        "formal": "(¬(A50 ∨ (A19 → A17)) → A51)",
        "prover9": "(-(A50 | (A19 -> A17)) -> A51)",
        "prover9_expression": "(-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> price_control(drug))",
        "natural": "If it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, then the drug is under price control."
      },
      "(¬(A50 ∨ (A19 → A17)) → ¬A51)": {
        "formal": "(¬(A50 ∨ (A19 → A17)) → ¬A51)",
        "prover9": "(-(A50 | (A19 -> A17)) -> -A51)",
        "prover9_expression": "(-(patient_assistance_program(drug) | (private_equity_investment(drug) -> venture_capital_funding(drug))) -> -price_control(drug))",
        "natural": "Whenever it is not the case that either the drug has a patient assistance program or if the drug receives private equity investment then the drug receives venture capital funding, the drug is not under price control."
      },
      "(¬(A61 ∨ (A60 → (A19 → A17))) → A62)": {
        "formal": "(¬(A61 ∨ (A60 → (A19 → A17))) → A62)",
        "prover9": "(-(A61 | (A60 -> (A19 -> A17))) -> A62)",
        "prover9_expression": "(-(formulary_inclusion(drug) | (reimbursement_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))) -> prior_authorization(drug))",
        "natural": "Provided that it is not the case that either the drug is included in a formulary or if the drug receives reimbursement approval then if the drug receives private equity investment then the drug receives venture capital funding, the drug requires prior authorization."
      },
      "(¬(A61 ∨ (A60 → (A19 → A17))) → ¬A62)": {
        "formal": "(¬(A61 ∨ (A60 → (A19 → A17))) → ¬A62)",
        "prover9": "(-(A61 | (A60 -> (A19 -> A17))) -> -A62)",
        "prover9_expression": "(-(formulary_inclusion(drug) | (reimbursement_approval(drug) -> (private_equity_investment(drug) -> venture_capital_funding(drug)))) -> -prior_authorization(drug))",
        "natural": "If it is not the case that either the drug is included in a formulary or if the drug receives reimbursement approval then if the drug receives private equity investment then the drug receives venture capital funding, then the drug does not require prior authorization."
      },
      "(¬(A66 → (A63 → A64)) → A67)": {
        "formal": "(¬(A66 → (A63 → A64)) → A67)",
        "prover9": "(-(A66 -> (A63 -> A64)) -> A67)",
        "prover9_expression": "(-(patent_settlement(drug) -> (generic_competition(drug) -> biosimilar_version(drug))) -> patent_infringement(drug))",
        "natural": "Given that it is not the case that if there is a patent settlement for the drug then if the drug faces generic competition then a biosimilar version of the drug is available, there is patent infringement for the drug."
      },
      "(¬(¬(A47 → (A43 → ¬A44)) → A48) → A49)": {
        "formal": "(¬(¬(A47 → (A43 → ¬A44)) → A48) → A49)",
        "prover9": "(-(-(A47 -> (A43 -> -A44)) -> A48) -> A49)",
        "prover9_expression": "(-(-(safety_monitoring(drug) -> (drug_interaction_issue(drug) -> -adverse_events(drug))) -> risk_management_plan(drug)) -> black_box_warning(drug))",
        "natural": "Provided that it is not the case that if it is not the case that if the drug undergoes safety monitoring then if the drug has a drug interaction issue then the drug does not have adverse events then the drug has a risk management plan, the drug has a black box warning."
      },
      "(¬(¬G → ¬A1) → A30)": {
        "formal": "(¬(¬G → ¬A1) → A30)",
        "prover9": "(-(-G -> -A1) -> A30)",
        "prover9_expression": "(-(-profitable(drug) -> -approved(technology,drug)) -> conditional_approval(drug))",
        "natural": "If it is not the case that if the drug is not profitable then the technology for the drug is not approved, then the drug receives conditional approval."
      },
      "(¬A6 → A7)": {
        "formal": "(¬A6 → A7)",
        "prover9": "(-A6 -> A7)",
        "prover9_expression": "(-has_patent_protection(drug) -> generic_version_available(drug))",
        "natural": "Whenever the drug does not have patent protection, a generic version of the drug is available."
      },
      "(¬A6 → ¬A7)": {
        "formal": "(¬A6 → ¬A7)",
        "prover9": "(-A6 -> -A7)",
        "prover9_expression": "(-has_patent_protection(drug) -> -generic_version_available(drug))",
        "natural": "Provided that the drug does not have patent protection, it is not the case that a generic version of the drug is available."
      },
      "(¬G → A1)": {
        "formal": "(¬G → A1)",
        "prover9": "(-G -> A1)",
        "prover9_expression": "(-profitable(drug) -> approved(technology,drug))",
        "natural": "If the drug is not profitable, then the technology for the drug is approved."
      },
      "(¬G → A8)": {
        "formal": "(¬G → A8)",
        "prover9": "(-G -> A8)",
        "prover9_expression": "(-profitable(drug) -> clinical_trial_completed(drug))",
        "natural": "Under the condition that the drug is not profitable, the clinical trial for the drug is completed."
      },
      "(¬G → ¬A1)": {
        "formal": "(¬G → ¬A1)",
        "prover9": "(-G -> -A1)",
        "prover9_expression": "(-profitable(drug) -> -approved(technology,drug))",
        "natural": "Provided that the drug is not profitable, the technology for the drug is not approved."
      },
      "(¬G → ¬A8)": {
        "formal": "(¬G → ¬A8)",
        "prover9": "(-G -> -A8)",
        "prover9_expression": "(-profitable(drug) -> -clinical_trial_completed(drug))",
        "natural": "If the drug is not profitable, then the clinical trial for the drug is not completed."
      },
      "A2": {
        "formal": "A2",
        "prover9": "A2",
        "prover9_expression": "submitted(application,regulatory_agency)",
        "natural": "An application is submitted to the regulatory agency."
      },
      "A32": {
        "formal": "A32",
        "prover9": "A32",
        "prover9_expression": "compliance_certificate(drug)",
        "natural": "The drug has a compliance certificate."
      },
      "A56": {
        "formal": "A56",
        "prover9": "A56",
        "prover9_expression": "patent_filing(drug)",
        "natural": "A patent is filed for the drug."
      },
      "A57": {
        "formal": "A57",
        "prover9": "A57",
        "prover9_expression": "patent_granted(drug)",
        "natural": "A patent is granted for the drug."
      },
      "A6": {
        "formal": "A6",
        "prover9": "A6",
        "prover9_expression": "has_patent_protection(drug)",
        "natural": "The drug has patent protection."
      },
      "G": {
        "formal": "G",
        "prover9": "G",
        "prover9_expression": "profitable(drug)",
        "natural": "The drug is profitable."
      },
      "¬A11": {
        "formal": "¬A11",
        "prover9": "-A11",
        "prover9_expression": "-manufacturing_issue(drug)",
        "natural": "It is not the case that there is a manufacturing issue with the drug."
      },
      "¬A15": {
        "formal": "¬A15",
        "prover9": "-A15",
        "prover9_expression": "-market_withdrawal(drug)",
        "natural": "It is not the case that the drug undergoes market withdrawal."
      },
      "¬A26": {
        "formal": "¬A26",
        "prover9": "-A26",
        "prover9_expression": "-counterfeit_product(drug)",
        "natural": "It is not the case that the drug is a counterfeit product."
      },
      "¬A28": {
        "formal": "¬A28",
        "prover9": "-A28",
        "prover9_expression": "-illegal_distribution(drug)",
        "natural": "It is not the case that the drug is distributed illegally."
      },
      "¬A29": {
        "formal": "¬A29",
        "prover9": "-A29",
        "prover9_expression": "-legal_distribution(drug)",
        "natural": "It is not the case that the drug is distributed legally."
      },
      "¬A30": {
        "formal": "¬A30",
        "prover9": "-A30",
        "prover9_expression": "-conditional_approval(drug)",
        "natural": "It is not the case that the drug receives conditional approval."
      },
      "¬A31": {
        "formal": "¬A31",
        "prover9": "-A31",
        "prover9_expression": "-full_approval(drug)",
        "natural": "It is not the case that the drug receives full approval."
      },
      "¬A35": {
        "formal": "¬A35",
        "prover9": "-A35",
        "prover9_expression": "-regulatory_violation(company)",
        "natural": "It is not the case that the company commits a regulatory violation."
      },
      "¬A36": {
        "formal": "¬A36",
        "prover9": "-A36",
        "prover9_expression": "-compliance_maintained(company)",
        "natural": "It is not the case that the company maintains compliance."
      },
      "¬A39": {
        "formal": "¬A39",
        "prover9": "-A39",
        "prover9_expression": "-orphan_drug_status(drug)",
        "natural": "It is not the case that the drug has orphan drug status."
      },
      "¬A42": {
        "formal": "¬A42",
        "prover9": "-A42",
        "prover9_expression": "-combination_therapy(drug)",
        "natural": "It is not the case that the drug is a combination therapy."
      },
      "¬A43": {
        "formal": "¬A43",
        "prover9": "-A43",
        "prover9_expression": "-drug_interaction_issue(drug)",
        "natural": "It is not the case that the drug has a drug interaction issue."
      },
      "¬A48": {
        "formal": "¬A48",
        "prover9": "-A48",
        "prover9_expression": "-risk_management_plan(drug)",
        "natural": "It is not the case that the drug has a risk management plan."
      },
      "¬A49": {
        "formal": "¬A49",
        "prover9": "-A49",
        "prover9_expression": "-black_box_warning(drug)",
        "natural": "It is not the case that the drug has a black box warning."
      },
      "¬A50": {
        "formal": "¬A50",
        "prover9": "-A50",
        "prover9_expression": "-patient_assistance_program(drug)",
        "natural": "It is not the case that the drug has a patient assistance program."
      },
      "¬A52": {
        "formal": "¬A52",
        "prover9": "-A52",
        "prover9_expression": "-value_based_pricing(drug)",
        "natural": "It is not the case that the drug uses value-based pricing."
      },
      "¬A55": {
        "formal": "¬A55",
        "prover9": "-A55",
        "prover9_expression": "-market_exclusivity(drug)",
        "natural": "It is not the case that the drug has market exclusivity."
      },
      "¬A61": {
        "formal": "¬A61",
        "prover9": "-A61",
        "prover9_expression": "-formulary_inclusion(drug)",
        "natural": "It is not the case that the drug is included in a formulary."
      },
      "¬A63": {
        "formal": "¬A63",
        "prover9": "-A63",
        "prover9_expression": "-generic_competition(drug)",
        "natural": "It is not the case that the drug faces generic competition."
      },
      "¬A67": {
        "formal": "¬A67",
        "prover9": "-A67",
        "prover9_expression": "-patent_infringement(drug)",
        "natural": "It is not the case that there is patent infringement for the drug."
      },
      "¬A68": {
        "formal": "¬A68",
        "prover9": "-A68",
        "prover9_expression": "-manufacturing_process(technology,drug)",
        "natural": "It is not the case that a manufacturing process uses technology for the drug."
      },
      "¬A72": {
        "formal": "¬A72",
        "prover9": "-A72",
        "prover9_expression": "-supply_chain_disruption(drug)",
        "natural": "It is not the case that the drug experiences a supply chain disruption."
      },
      "¬A73": {
        "formal": "¬A73",
        "prover9": "-A73",
        "prover9_expression": "-production_delayed(drug)",
        "natural": "It is not the case that production of the drug is delayed."
      },
      "¬A76": {
        "formal": "¬A76",
        "prover9": "-A76",
        "prover9_expression": "-storage_violation(drug)",
        "natural": "It is not the case that there is a storage violation for the drug."
      },
      "¬A77": {
        "formal": "¬A77",
        "prover9": "-A77",
        "prover9_expression": "-temperature_excursion(drug)",
        "natural": "It is not the case that the drug experiences a temperature excursion."
      },
      "¬A79": {
        "formal": "¬A79",
        "prover9": "-A79",
        "prover9_expression": "-quality_assurance(drug)",
        "natural": "It is not the case that the drug undergoes quality assurance."
      },
      "¬A80": {
        "formal": "¬A80",
        "prover9": "-A80",
        "prover9_expression": "-batch_testing(drug)",
        "natural": "It is not the case that the drug undergoes batch testing."
      },
      "¬A81": {
        "formal": "¬A81",
        "prover9": "-A81",
        "prover9_expression": "-stability_study(drug)",
        "natural": "It is not the case that the drug undergoes a stability study."
      }
    }
  }
}